Dataset Viewer
text
stringlengths 102
99.6k
| url
stringlengths 31
426
| crawl_date
timestamp[us, tz=UTC]date 2022-04-01 00:29:49
2022-09-19 04:34:15
|
|---|---|---|
Ruling clears Biden’s 2021 pause on new oil, gas leases
NEW ORLEANS (AP) — A judge’s order that forced the Biden administration to resume sales of oil and gas leases on federal land and waters was vacated Wednesday by a federal appeals court in New Orleans.
It was at least a temporary victory for President Joe Biden but the immediate effect was unclear.
The much-heralded climate bill that Biden signed into law Tuesday provides for new drilling opportunities, in a compromise among Democrats, and mandates that several lease sales be held over the next year in the Gulf of Mexico and Alaska.
Biden had signed an executive order that suspended new lease sales soon after taking office in 2021. The following March, U.S. District Judge Terry Doughty in Monroe, Louisiana, blocked the policy, siding with more than a dozen Republican-leaning states opposed to Biden’s move.
The appeals court in New Orleans on Wednesday said the judge’s reasons were unclear and sent the case back to him.
“We cannot reach the merits of the Government’s challenge when we cannot ascertain from the record what conduct — an unwritten agency policy, a written policy outside of the Executive Order, or the Executive Order itself — is enjoined,” Judge Patrick Higginbotham wrote for a panel that also included judges James Dennis and James Graves.
Department of the Interior officials were reviewing the decision, spokesperson Melissa Schwartz said. She declined to say whether the climate law made the issue moot.
The practical impacts of the ruling could be minor because of the fossil fuel leasing mandates in the climate law, said Erik Milito, president of the National Ocean Industries Association, which represents oil and gas companies.
The law requires the government to reinstate $192 million in leases in the Gulf of Mexico that were blocked by another court ruling last year. And it requires two more sales in the Gulf and one in Alaska before October 2023. Those sales had been canceled under Biden. The provision reviving them was inserted into the law at the insistence of West Virginia Democratic Sen. Joe Manchin, an advocate for fossil fuels.
Going forward the law says Interior will hold periodic oil and gas lease sales and offer at least 60 million acres (24 million hectares) of offshore parcels and 2 million acres (810,000 hectares) onshore during the prior year before it can approve any renewable energy leases.
“Offshore oil and gas leasing has been protected and will proceed,” said Milito.
Environmentalists remained hopeful that the ruling would prompt the administration to move forward with other changes to the oil and gas leasing program, such as limits on future development including where leasing occurs.
“They may not be able to deliver a full moratorium on leasing, but at least they can exercise more restraint than they could with the injunction in place,” said Jeremy Nichols with the environmental group WildEarth Guardians. “All eyes are going to be on the Interior Department to see what their next move might be.”
Following last year’s injunction from Doughty that forced lease sales to resume, the Biden administration auctioned off more than 2,700 square miles (6,950 square kilometers) of leases in the Gulf of Mexico in November. The sale was later overturned by a federal judge in Washington D.C., who said the government had failed to adequately consider climate change impacts from burning oil and gas from the Gulf.
In June, the administration sold leases on about 110 square miles (285 square kilometers) of federal land, mostly in Wyoming, despite concluding that future emissions from the parcels offered could cause billions of dollars in damages due to climate change impacts. Legal challenges of those sales by environmentalists are pending.
Doughty was appointed to the federal bench by former President Donald Trump. Higginbotham was appointed to the appeals court by former President Ronald Reagan; Dennis, by former President Bill Clinton; Graves, by former President Barack Obama.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wibw.com/2022/08/17/ruling-clears-bidens-2021-pause-new-oil-gas-leases/
| 2022-08-18T00:13:46 |
Limited Reservations for the Culinary Experience available on OpenTable beginning August 4
ST. LOUIS, July 26, 2022 /PRNewswire/ -- Fancy Feast, the most popular brand of gourmet wet cat food in the U.S., announced today the opening of "Gatto Bianco by Fancy Feast", a limited-time, Italian-style trattoria and culinary experience in New York City, to celebrate its new globally inspired Medleys recipes. Gatto Bianco will bring the mealtime experience of cats to life for cat owners and cat lovers and includes a special appearance by the iconic Fancy Feast cat herself. The dishes (for humans!) take inspiration from Fancy Feast Medleys recipes and pay homage to traditional Italian cuisine, with a menu developed by Fancy Feast's in-house chef, Amanda Hassner, along with Michelin Star winning Italian chef and acclaimed New York restaurateur Cesare Casella.
Located between the Far West Village and the Meatpacking District in New York City, Gatto Bianco will be open for dinner on Thursday, August 11 and Friday, August 12 only, with four reservations per evening at 6:30 p.m. ET. Each reservation will accommodate two guests (ages 21+). The 16 lucky cat lovers will enjoy a complimentary tasting menu that will transport them to Italy for the evening, as Chef Casella shares his Italian heritage and passion for cooking with a menu of authentic, Tuscan dishes, while Chef Hassner shares her culinary expertise to mirror the sensory experience of cats at mealtime.
"Food has the power to connect us to others in meaningful ways and take us to places we have never been," said Hassner. "The same is true for our cats. The dishes at Gatto Bianco are prepared in ways that help cat owners understand how their cats experience food – from flavor, to texture, to form – in a way that only Fancy Feast can."
The chefs will provide guests an inside look at the detail and expertise that goes into crafting each Fancy Feast recipe through a variety of delectable dishes and culinary exercises. The Gatto Bianco experience builds on the success of the Fancy Feast cookbook, launched in 2021, and is the newest way that Fancy Feast is showing cat owners the delight it brings to cats at every meal.
Reservations for Gatto Bianco will open for booking on Thursday, August 4 at 12:00 p.m. ET through OpenTable. Cat enthusiasts can visit FancyFeast.com/Reservations to try to secure their spot and for more information. Reservations are limited and based on availability.
And for those who can't come to Gatto Bianco – let Gatto Bianco come to you! Fancy Feast is sharing recipes inspired by the Gatto Bianco menu so that cat lovers across the country can have an exceptional dining experience right in their own homes. Visit www.fancyfeast.com to download the recipes.
Fancy Feast Medleys are now available at select retailers nationwide for a suggested retail price of $1.13. For more information on Medleys visit FancyFeast.com.
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations. Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations. Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
View original content to download multimedia:
SOURCE Purina
|
https://www.kxii.com/prnewswire/2022/07/26/fancy-feast-introduces-gatto-bianco-an-italian-trattoria-cat-lovers/
| 2022-07-26T19:50:13 |
MILWAUKEE, Aug. 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Aerie (NASDAQ: AERI) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon.
Click here to learn how to join the action: https://www.ademilaw.com/case/aerie-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges Aerie's financial outlook and prospects are excellent and yet Aerie holders will receive only $15.25 per share representing an equity value of approximately $770 million. The transaction agreement unreasonably limits competing bids for Aerie by imposing a significant penalty if Aerie accepts a superior bid. Aerie insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Aerie's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Aerie.
If you own Aerie common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/aerie-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:
SOURCE Ademi LLP
|
https://www.wibw.com/prnewswire/2022/08/23/shareholder-alert-ademi-llp-investigates-whether-aerie-pharmaceuticals-inc-has-obtained-fair-price-its-transaction-with-alcon/
| 2022-08-23T15:14:28 |
NEW YORK , June 27, 2022 /PRNewswire/ -- Athonet, a global leader in private network technology, today announced the 5G Consortium which brings together a vendor ecosystem of companies and organizations to promote the deployment of private mobile networks.
The goal of the 5G Consortium is to mutually promote an ecosystem of products and services that support LTE, 5G and CBRS private network deployments; collaborate in marketing the consortium; and conduct testing between products to ensure solutions are interoperable with each other and within the private LTE and 5G cellular environment.
"iGR sees a great opportunity for private wireless networks in the enterprise in the coming years," said Iain Gillot, president of iGR. "To be successful, the industry needs to deliver and support complete integrated solutions to the enterprise - this will require partnerships of the kind the 5G Consortium is building. The 5G Consortium is delivering solutions the enterprise private wireless network market needs."
"We are seeing an immense increase in interest to explore the benefits of private networks," said Simon O'Donnell, president, Athonet USA. "However, some companies aren't sure of what technologies are needed, the products that are available and work together, or the companies that are available to help design, implement and maintain a private network. The 5G Consortium simplifies the process and helps enterprises understand what is needed and find the right solution."
The 5G Consortium includes consultants, systems integrators and post-deployment specialists that can help match the business need with radios, devices and appliances that are interoperable with the Athonet mobile core. Current members of the 5G Consortium include:
Mike Owen, chief technology officer, Bearcom
"One of the biggest challenges customers face when adopting new technology is how to perform the implementation. For 40 years, BearCom has been providing the end-to-end solutions to successfully deploy innovative technologies. We partner with other organizations, through the 5G Consortium, to navigate any obstacles while working directly with the customer on their journey to success."
Andy Germano, vice president, Business Development, BEC Technologies
"We are excited about joining the 5G Consortium and the opportunity to collaborate and work with well-established industry partners to drive adoption of private mobile networks."
Patrick Buthmann, vice president, Sales & Business Development, BLiNQ Networks
"We are excited to be part of the 5G Consortium and understand the need for robust and reliable wireless solutions which are easy to deploy and are accessible to customers who have varying network requirements. We are firm believers that through collaboration and technology leadership, we can successfully distill the power and value of private LTE and 5G networks."
Harald Remmert, chief technology officer, Cellular Solutions, Digi International
"Digi is extremely proud to join the 5G Consortium as a founding member. Digi's IoT Connectivity Solutions connect people, places, and machines in the most demanding environments – reliably, securely, and proven for over 35 years. We are inspired by 5G Consortium's vision to accelerate private 4G/5G Networks adoption, which we believe will be a catalyst for remote connectivity, infrastructure modernization and digital transformation."
Chris Swan, chief commercial officer, Federated Wireless
"The reality is that next-generation wireless solutions are the key to helping enterprises realize the full potential of their cloud edge and IoT investments. The challenge is that most customers don't know where to start. That's why Federated Wireless is thrilled to support the 5G Consortium in reaching more customers, specifically by helping design, deliver and manage private wireless solutions that meet the exact use case requirements and goals of the business."
Brendon Mills, chief executive officer, Fortress Solutions
"With 5G deployments growing rapidly throughout not only the U.S. but world-wide, the 5G Consortium is an organization that provides an interoperability safe-haven for those organizations installing multi-vendor LTE, 5G, and CBRS private networks. Fortress Solutions is excited to be a partner of the consortium and to offer post-deployment/day 2 services to all customers looking to maintain, grow and optimize their networks."
Dan Quant, vice president, Strategic Development, MultiTech Systems
"MultiTech is honored to join Athonet Consortium accelerating Enterprise Cellular Network scalability across market segments," said Daniel Quant, Vice President of Strategic Development at MultiTech. "Compatibility amongst device, network and service members of the consortium reduces the time and costs to securely digitize assets and workflows."
Arif Ahsan, Director of Business Development, Supermicro Computer, Inc.
The 5G Consortium, launched by Athonet, is a timely collaborative response to enterprise demands. Supermicro believes that enterprise private networks are poised to become mainstream and is excited to be a partner with its broad array of industry leading edge appliances."
Andrew Davies, Chief Executive Officer, Syniverse Technologies, LLC
"Athonet has assembled an impressive vendor ecosystem to promote the deployment of private networks, an increasingly relevant and widespread market interest. With more than three decades of experience providing the most comprehensive platform to unlock the full potential of communication technologies, Syniverse is pleased to be an inaugural member of Athonet's Private Mobile Network Consortium. We look forward to working with the consortium members – present and future state – to help enterprises manage their critical communication needs on both private and public networks."
Athonet is a leader in private cellular network technology delivering a mobile core to enterprises and communication service providers to connect applications, devices and radios. With more than 10 years of experience in delivering 4G/5G mobile core solutions to customers and partners in every region of the world, Athonet supports key industries where network control, mobility, security, performance, reliability and cost are important for business outcomes. Find out more www.athonet.com.
View original content to download multimedia:
SOURCE Athonet
|
https://www.mysuncoast.com/prnewswire/2022/06/27/5g-consortium-promotes-solutions-private-mobile-networks-with-athonet-mobile-core/
| 2022-06-27T13:05:53 |
SAN FRANCISCO, July 15, 2022 /PRNewswire/ -- DoorDash, Inc. (NYSE: DASH) today announced that the company's second quarter 2022 financial results will be released after market close on Thursday, August 4, 2022. The company's earnings press release and shareholder letter will be made available on the DoorDash Investor Relations website at ir.doordash.com.
DoorDash will host a conference call to discuss its results at 3 p.m. PT / 6 p.m. ET the same day. Interested parties may register for and access the live webcast of the call at the DoorDash Investor Relations website at ir.doordash.com. Following the call, a replay will be available at the same website.
DoorDash announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, webcasts, the investor relations section of its website (ir.doordash.com), and its blog (doordash.news) in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
About DoorDash
DoorDash (NYSE: DASH) is a technology company that connects consumers with their favorite businesses in 27 countries across the globe. Founded in 2013, DoorDash enables local businesses to address consumers' expectations of ease and immediacy and thrive in today's convenience economy. By building the logistics infrastructure for local commerce, DoorDash is bringing communities closer, one doorstep at a time.
Investor Relations Contact
[email protected]
Press Contact
[email protected]
View original content to download multimedia:
SOURCE DoorDash
|
https://www.mysuncoast.com/prnewswire/2022/07/15/doordash-announce-second-quarter-2022-results-august-4-2022/
| 2022-07-15T14:55:51 |
Morant-Curry duel center of Grizzlies-Warriors showdown
By TERESA M. WALKER
AP Sports Writer
MEMPHIS, Tenn. (AP) — Ja Morant and Stephen Curry are two of the NBA’s most entertaining players. If they continue to perform the way they did in the Game 1 of the Grizzlies-Warriors series, basketball fans are in for a treat. Morant looked nearly unstoppable with his acrobatic drives to the basket. Curry was Curry, taking and knocking down step-back 3s. No, they didn’t disappoint. But down the stretch, Curry and Golden State found a way to derail Morant and give the Warriors a 1-0 series lead. Basketball fans should stay tuned to see what comes next in the postseason showdown between the league’s Most Improved Player and All-Star point guard in Morant against two-time NBA MVP Curry.
|
https://localnews8.com/sports/ap-national-sports/2022/05/02/morant-curry-duel-center-of-grizzlies-warriors-showdown/
| 2022-05-02T11:09:25 |
NEW YORK, Aug. 26, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Enochian BioSciences, Inc. (NASDAQ: ENOB).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/enochian-biosciences-inc-loss-submission-form/?id=31166&from=4
The lawsuit seeks to recover losses for shareholders who purchased Enochian between January 17, 2018 and June 27, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until September 26, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Enochian BioSciences, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content:
SOURCE Jakubowitz Law
|
https://www.kxii.com/prnewswire/2022/08/26/enob-shareholder-alert-jakubowitz-law-reminds-enochian-shareholders-lead-plaintiff-deadline-september-26-2022/
| 2022-08-26T10:15:28 |
BLOOMFIELD HILLS, Mich., Aug. 11, 2022 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.234 per common share. The monthly dividend reflects an annualized dividend amount of $2.808 per common share, representing a 7.8% increase over the annualized dividend amount of $2.604 per common share from the third quarter of 2021. The dividend is payable September 14, 2022 to stockholders of record at the close of business on August 31, 2022.
Additionally, the Company's Board of Directors has authorized, and the Company has declared, a monthly cash dividend on its 4.25% Series A Cumulative Redeemable Preferred Stock of $0.08854 per depositary share, which is equivalent to $1.0625 per annum. The dividend is payable September 1, 2022 to stockholders of record at the close of business on August 22, 2022.
Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of June 30, 2022, the Company owned and operated a portfolio of 1,607 properties, located in all 48 continental states and containing approximately 33.8 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC". For additional information on the Company and RETHINKING RETAIL, please visit www.agreerealty.com.
View original content to download multimedia:
SOURCE Agree Realty Corporation
|
https://www.kxii.com/prnewswire/2022/08/11/agree-realty-declares-monthly-common-preferred-dividends/
| 2022-08-11T21:20:20 |
Manatee man gets 14 years for 1998 assault
BRADENTON, Fla. (WWSB) - A Manatee County man convicted of sexually battering a 13-year old girl in 1998 will spend the next 14 years in jail.
Gregory Milton Laverne Johnson was sentenced Thursday to 14 years, 3 months and 15 days in prison, and will also have to register as a sex offender, State Attorney Ed Brodsky’s Office said.
The investigation over the course of 24 years revealed that on May 10, 1998, the victim was home alone while her babysitter and others went to Ybor City.
Johnson entered the victim’s bedroom and sexually battered her while she was asleep and then fled the area. The victim was taken by her babysitter to Manatee Memorial Hospital where evidence was collected.
In September 2019, the Florida Department of Law Enforcement reported that a match occurred between the DNA profile obtained from the victim and Johnson. He was arrested in Georgia and extradited to Florida.
“Thanks to scientific evidence and Law Enforcement efforts, our community is now safer,” Assistant State Attorney Casey Cahall, the lead prosecutor, said.
Copyright 2022 WWSB. All rights reserved.
|
https://www.mysuncoast.com/2022/06/09/manatee-man-gets-14-years-1998-assault/
| 2022-06-09T17:43:36 |
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Attention Yext, Inc. ("Yext") (NYSE: YEXT) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 4, 2021 and March 8, 2022.
If you suffered a loss on your investment in Yext, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Yext includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Yext's revenue and earnings were significantly deteriorating because of, among other things, poor sales execution and performance, as well as COVID-19 related disruptions; (ii) accordingly, Yext was unlikely to meet consensus estimates for its full year fiscal 2022 financial results and fiscal 2023 outlook; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: August 16, 2022
Aggrieved Yext investors only have until August 16, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: [email protected]
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.mysuncoast.com/prnewswire/2022/08/15/class-action-alert-law-offices-vincent-wong-remind-yext-investors-lead-plaintiff-deadline-august-16-2022/
| 2022-08-15T11:20:14 |
HOVER recognized for its powerful technology leveraging property data to transform the claims process for insurers and homeowners
SAN FRANCISCO, June 15, 2022 /PRNewswire/ -- HOVER, the technology company that transforms smartphone photos of any property into a digital twin with valuable 3D data, was named to CB Insights' first annual Insurtech 50, which showcases the 50 most promising private insurtech companies across the globe.
HOVER's mission is to help people improve their homes with the world's best 3D property data by providing insurers and homeowners with transparent, accurate and actionable data. Its end-to-end platform and multifaceted technology is leveraged by insurance professionals to enable a more efficient workflow and in turn, unlock a faster claims process for policyholders. With just a few smartphone photos, HOVER's mobile app allows users to scan the exterior of a property with real-time guidance to generate an accurately-measured, and fully-interactive, 3D model of the home – in a matter of minutes.
"HOVER makes the difficult and often emotional process of home restoration more collaborative, efficient, and transparent," said A.J. Altman, founder and CEO of HOVER. "We're honored to be recognized for the technology our team has built to help people improve their homes and complete insurance claims leveraging the world's best 3D property data."
HOVER's significant growth, traction, and adoption among some of the nation's top insurance carriers, building contractors, and distributors is a testament not only to its unparalleled innovation, but also to its potential to redefine industries – like insurance and construction – that have been challenged by process inefficiencies for decades.
"The companies in our inaugural Insurtech 50 have built and harnessed new technologies to improve all aspects of the insurance value chain, from customer acquisition to underwriting and claims for a variety of different insurance products," said Brian Lee, SVP of CB Insights' Intelligence Unit. "Together they are accelerating innovation across an industry that directly impacts human health and well-being."
Using the CB Insights platform, the research team picked these 50 private market vendors from a pool of over 2,000 companies, including applicants and nominees. They were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed hundreds of Analyst Briefings submitted by applicants.
For those wanting to learn more about the Insurtech 50 and the selection process, please register for the webinar, Behind the Scenes of the Insurtech 50, on June 15, 2022 at 2:00 pm EST.
HOVER is developing an accurate and usable data set of physical property to deliver a simpler and more transparent home improvement experience. Used by contractors, insurance adjusters and homeowners alike, HOVER drives efficiencies with a mobile app that measures, designs, and estimates costs all in one place; smartphone photos transform into beautifully rendered, fully-measured 3D models of any home. For more information, visit hover.to.
HOVER Press Contact
Kira Wolfe
[email protected]
CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
CB Insights Press Contact
[email protected]
View original content to download multimedia:
SOURCE HOVER
|
https://www.mysuncoast.com/prnewswire/2022/06/15/cb-insights-names-hover-one-top-50-most-innovative-insurtech-startups-2022/
| 2022-06-15T13:53:47 |
TEL AVIV, Israel, June 13, 2022 /PRNewswire/ -- The robotic combat vehicle will be unveiled today at Elbit Systems' pavilion at the Eurosatory Defense and Security Exhibition. The vehicle includes a new robotic platform *type BLR-2 made by BL*, a 30 mm autonomous turret developed by the Tank and APC Directorate for the 'Eitan' APC, Elbit's 'Iron Fist' Active Protection System, fire control and mission management systems, and robotic autonomous kit, in addition to situation awareness systems. The vehicle also features a capsuled drone for forward reconnaissance missions, and a passive sensing kit developed by Elbit Systems and Foresight.
The technological demonstrator, led by the Ministry of Defense's DDR&D and the Tank and APC Directorate, integrates a number of cutting-edge technologies including advanced maneuvering capabilities, the ability to carry heavy and varied mission loads, and a built-in system for transporting and receiving UAVs.
The vehicle will also incorporate sights, an IAI missile launcher, and Rafael Advanced Defense Systems' 'Spike' missiles. The M-RCV's capabilities include a highly autonomous solution for forward reconnaissance, and controlled lethality in all-terrain conditions. It is operational during the day and night in all-weather scenarios, while emphasizing operational effectiveness, simplicity, minimum operator intervention, and integration into heterogeneous unmanned arrays.
The system was developed as part of the autonomous battlefield concept led in the DDR&D in collaboration with the Tank and APC Directorate while implementing an open architecture for integrating future capabilities and integrating the robot alongside other tools and capabilities.
The system is a joint product of many years of investment by the DDR&D and the Tank and APC Directorate and is expected to start field tests during 2023 in representative scenarios.
Video: https://www.youtube.com/watch?v=hNLCa6isqJA
Photo: https://mma.prnewswire.com/media/1838057/ROBUST_IMOD_Elbit_Combat_Vehicle.jpg
Photo: https://mma.prnewswire.com/media/1838058/ROBUST_IMOD_Elbit_Combat_Vehicle_2.jpg
Logo: https://mma.prnewswire.com/media/1838055/Israel_Ministry_of_Defense_Logo.jpg
View original content to download multimedia:
SOURCE Israel Ministry of Defense
|
https://www.kxii.com/prnewswire/2022/06/13/israel-ministry-defense-will-begin-testing-robotic-unmanned-vehicle-m-rcv-medium-robotic-combat-vehicle-developed-by-ministrys-directorate-defense-research-development-ddrampd-tank-apc-directorate-israeli-security-industries/
| 2022-06-13T07:49:49 |
ATLANTA — Republican U.S. Senate candidate Herschel Walker is leading incumbent Democratic Sen. Raphael Warnock by 10 points, according to a poll released Wednesday by a political action committee supporting the University of Georgia football great.
The survey of 2,500 registered Georgia voters put Walker at 51.4%, compared to 41% for Warnock. The poll was conducted from April 3-16 via landline telephones, cellphones and texts by Alexandria, Va.-based Grassroots Targeting on behalf of Walker’s 34N22 PAC.
34N22 noted in a memo that Walker has built a double-digit lead despite the Warnock campaign blanketing the airwaves with more than $7 million so far this year in ad spending.
“Barring a monumental shift in the political landscape, Herschel Walker is in prime position to be the next United States senator from the state of Georgia,” Republican strategist and Grassroots Targeting founder and CEO Blaise Hazelwood wrote in the memo.
Walker can afford to look beyond next month’s Republican primary to a November general election matchup with Warnock. The GOP frontrunner is polling well ahead of several other Republican Senate hopefuls, whose combined support doesn’t come close to matching his numbers.
The Grassroots Targeting poll also found President Joe Biden’s approval ratings on the decline in Georgia. Only 43.8% of voters surveyed approve of the job Biden is doing, while his approval rating among independents was even lower at 41.9%.
The poll found Warnock’s approval rating at 45.2%.
Warnock has only token Democratic primary opposition in his bid to win a full six-year term in the Senate. He won the seat in a special election runoff in January of last year, defeating incumbent Republican Kelly Loeffler, who had been appointed to the Senate by Gov. Brian Kemp following the retirement of the late Sen. Johnny Isakson in 2019.
The poll had a margin of error of plus-or-minus 1.96%.
Multiple emergency response agencies responded on Wednesday to a simulated airplane crash at Southwest Georgia Regional Airport. Airport firefighters put out a small fire before paramedics hit the scene to assist patients made up to display a variety of mock injuries. The exercise was part o… Click for more.
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
|
https://www.albanyherald.com/news/internal-poll-shows-walker-with-10-point-lead-over-warnock/article_ea9139a8-c651-11ec-8ceb-2319fe6f34dc.html
| 2022-04-27T22:20:09 |
DUBAI, United Arab Emirates (AP) — Iran appeared to be readying for a space launch Tuesday as satellite images showed a rocket on a rural desert launch pad, just as tensions remain high over Tehran’s nuclear program.
The images from Maxar Technologies showed a launch pad at Imam Khomeini Spaceport in Iran’s rural Semnan province, the site of frequent recent failed attempts to put a satellite into orbit.
One set of images showed a rocket on a transporter, preparing to be lifted and put on a launch tower. A later image Tuesday afternoon showed the rocket apparently on the tower.
Iran did not acknowledge a forthcoming launch at the spaceport and its mission to the United Nations in New York did not immediately respond to a request for comment.
However, its state-run IRNA news agency in May said that Iran likely would have seven homemade satellites ready for launch by the end of the Persian calendar year in March 2023. A Defense Ministry official also recently suggested Iran soon could test its new solid-fueled, satellite-carrying rocket called the Zuljanah.
It wasn’t clear when the launch would take place, though erecting a rocket typically means a launch is imminent. NASA fire satellites, which detect flashes of light from space, did not immediately see any activity over the site late Tuesday night.
Asked about the preparations, State Department spokesman Ned Price told reporters in Washington that the U.S. urges Iran to de-escalate the situation.
“Iran has consistently chosen to escalate tensions. It is Iran that has consistently chosen to take provocative actions,” Price said.
A Pentagon spokesman, U.S. Army Maj. Rob Lodewick, said the American military “will continue to closely monitor Iran’s pursuit of viable space launch technology and how it may relate to advancements in its overall ballistic missile program.”
“Iranian aggression, to include the demonstrated threat posed by its various missile programs, continues to be a top concern for our forces in the region,” Lodewick said.
Over the past decade, Iran has sent several short-lived satellites into orbit and in 2013 launched a monkey into space. The program has seen recent troubles, however. There have been five failed launches in a row for the Simorgh program, a type of satellite-carrying rocket. A fire at the Imam Khomeini Spaceport in February 2019 also killed three researchers, authorities said at the time.
The launch pad used in Tuesday’s preparations remains scarred from an explosion in August 2019 that even drew the attention of then-President Donald Trump. He later tweeted what appeared to be a classified surveillance image of the launch failure. Satellite images from February suggested a failed Zuljanah launch earlier this year, though Iran did not acknowledge it.
The successive failures raised suspicion of outside interference in Iran’s program, something Trump himself hinted at by tweeting at the time that the U.S. “was not involved in the catastrophic accident.” There’s been no evidence offered, however, to show foul play in any of the failures, and space launches remain challenging even for the world’s most successful programs.
Meanwhile, Iran’s paramilitary Revolutionary Guard in April 2020 revealed its own secret space program by successfully launching a satellite into orbit. The Guard launched another satellite this March at another site in Semnan province, just east of the Iranian capital of Tehran.
Judging from the launch pad used, Iran likely is preparing for the Zuljanah test launch, said John Krzyzaniak, a research associate at the International Institute for Strategic Studies. Krzyzaniak earlier this week suggested a launch was imminent based on activity at the site.
The rocket’s name, Zuljanah, comes from the horse of Imam Hussein, the grandson of the Prophet Muhammad. Iranian state television aired footage of a successful Zuljanah launch in February 2021.
The launch preparations also come as the Guard reportedly saw one of its soldiers “martyred” in Semnan province under unclear circumstances over the weekend. Iran’s Defense and Armed Forces Logistics Ministry, however, later claimed the man worked for it.
The United States has alleged that Iran’s satellite launches defy a U.N. Security Council resolution and has called on Tehran to undertake no activity related to ballistic missiles capable of delivering nuclear weapons. The U.S. intelligence community’s 2022 threat assessment, published in March, claims such a satellite launch vehicle “shortens the timeline” to an intercontinental ballistic missile for Iran as it uses “similar technologies.”
Iran, which has long said it does not seek nuclear weapons, previously maintained that its satellite launches and rocket tests do not have a military component. U.S. intelligence agencies and the International Atomic Energy Agency say Iran abandoned an organized military nuclear program in 2003.
However, Iran’s likely preparations for a launch come as tensions have been heightened in recent days over Tehran’s nuclear program. Iran now says it will remove 27 IAEA surveillance cameras from its nuclear sites as it now enriches uranium closer than ever to weapons-grade levels.
Both Iran and the U.S. insist they are willing to re-enter Tehran’s 2015 nuclear deal with world powers, which saw the Islamic Republic drastically curb its enrichment in exchange for the lifting of economic sanctions. Trump unilaterally withdrew America from the accord in 2018, setting in motion a series of attacks and confrontations beginning in 2019 that continue today into the administration of President Joe Biden.
Talks in Vienna about reviving the deal have been on a “pause” since March.
Building a nuclear bomb would still take Iran more time if it pursued a weapon, analysts say, though they warn Tehran’s advances make the program more dangerous. Israel has threatened in the past that it would carry out a preemptive strike to stop Iran — and already is suspected in a series of recent killings targeting Iranian officials.
___
Follow Jon Gambrell on Twitter at www.twiter.com/jongambrellAP.
|
https://cw33.com/news/international/ap-international/satellite-images-suggest-iran-preparing-for-rocket-launch/
| 2022-06-15T01:07:15 |
Rangers’ Scottish Cup win eases Europa League pain
GLASGOW, Scotland (AP) — Rangers has ended a tumultuous week by winning the Scottish Cup after beating Hearts 2-0 after extra time in the final. Rangers lost the Europa League final on Wednesday night in a penalty shootout. It went into another extra time on Saturday thanks to Craig Gordon’s save with his foot from Joe Aribo near the end of regulation time at Hampden Park. However, they dug deep yet again and two goals in three minutes by substitutes Ryan Jack and Scott Wright gave them the Scottish Cup for the first time since 2009.
|
https://localnews8.com/news/2022/05/21/rangers-scottish-cup-win-eases-europa-league-pain/
| 2022-05-21T23:49:18 |
SEATTLE, July 8, 2022 /PRNewswire/ --
United States District Court
SOUTHERN District of CALIFORNIA
SUMMARY NOTICE OF (I) PROPOSED CLASS ACTION SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEES, REIMBURSEMENT OF LITIGATION EXPENSES, AND LEAD PLAINTIFF'S SERVICE AWARD
This notice is for all persons who purchased or otherwise acquired shares of the publicly traded common stock of BofI Holding, Inc. (now known as Axos Financial, Inc.), as well as purchasers of BofI call options and sellers of BofI put options, between September 4, 2013 through and including October 13, 2015. Certain persons and entities are excluded from the Class as set forth in detail in the Stipulation and Agreement of Settlement dated April 13, 2022 ("Stipulation") and the Notice described below.
PLEASE READ THIS NOTICE CAREFULLY; YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of California ("Court"), that the parties to the above-captioned action ("Action") have reached a proposed settlement for $14,100,000 in cash ("Settlement") that, if approved, will resolve all claims in the Action.
A hearing will be held on October 7, 2022, at 1:30 p.m., before the Honorable Gonzalo P. Curiel at the United States District Court for the Southern District of California, Edward J. Schwartz United States Courthouse, Courtroom 2D, 221 West Broadway, San Diego, CA 92101, to determine: (i) whether the proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the releases specified and described in the Stipulation (and in the Notice described below) should be entered; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Class Counsel's application for an award of attorneys' fees and reimbursement of expenses, and Lead Plaintiff's application for a service award, should be approved.
If you are a member of the Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund. This notice provides only a summary of the information contained in the detailed Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for an Award of Attorneys' Fees and Reimbursement of Litigation Expenses and Lead Plaintiff's Service Award ("Notice"). You may obtain a copy of the Notice, along with the Claim Form, on the website for the Settlement, www.BofISecuritiesLitigation.com. .You may also obtain copies of the Notice and Claim Form by contacting the Claims Administrator at In re BofI Holding, Inc. Securities Litigation Settlement, c/o JND Legal Administration, P.O. Box 91425, Seattle, WA 98111; 1-888-921-1538; [email protected].
If you are a member of the Class, in order to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than November 7, 2022, in accordance with the instructions set forth in the Claim Form. If you are a Class Member and do not submit a proper Claim Form, you will not be eligible to share in the distribution of the net proceeds of the Settlement but you will nevertheless be bound by any releases, judgments or orders entered by the Court in the Action.
If you are a member of the Class and wish to exclude yourself from the Class, you must submit a request for exclusion such that it is postmarked no later than August 8, 2022, in accordance with the instructions set forth in the Notice. If you properly exclude yourself from the Class, you will not be bound by any releases, judgments or orders entered by the Court in the Action and you will not be eligible to share in the net proceeds of the Settlement. Excluding yourself is the only option that may allow you to be part of any other current or future lawsuit against Defendants or any of the other released parties concerning the claims being resolved by the Settlement. Please note, however, if you decide to exclude yourself from the Class, you may be time-barred from asserting the claims covered by the Action by a statute of repose.
If you are a member of the Class and previously requested exclusion, you now have the opportunity to opt-back into the Class and participate in the Settlement. If you elect to opt-back into the Class, you will be able to submit a Claim Form and be eligible to share in the distribution of the net proceeds of the Settlement. If you elect to opt-back into the Class, you will be bound by any releases, judgments or orders entered by the Court in the Action, regardless of whether or not you submit a Claim Form.
Class Counsel will apply to the Court to be paid from the Settlement Fund, and any payment will be made only in the amount that is approved by the Court. Class Counsel will ask the Court for an award of attorneys' fees of no more than 25% of the Settlement Fund (i.e., no more than $3,525,000). In addition, Class Counsel will ask the Court to reimburse them out of the Settlement Fund for the expenses they reasonably incurred and will incur in litigating this case on behalf of Class Members, in an amount not to exceed $1,400,000. Class Counsel will also ask the Court to approve a Service Award of up to $15,000 for the Class Representative as an award for its service to the Class as Plaintiff and Class Representative out of the Settlement Fund. Class Counsel will also request authorization to pay the Claims Administrator, directly from the Settlement Fund, all Notice and Administration Costs actually incurred and paid or payable up to $350,000, which Class Counsel and the Claims Administrator estimate to be the maximum amount likely to be required. Any amount in excess of that would be payable from the Settlement Fund only upon further approval of the Court. The amount of the Settlement Fund that remains after the payment of all Court-approved attorneys' fees, reimbursement of expenses, Service Award, and Notice and Administration Costs will be distributed to Class Members who have submitted valid claims for compensation and have not timely excluded themselves from the Settlement in a manner approved by the Court.
Any objections to the proposed Settlement, the proposed Plan of Allocation, and/or Class Counsel's motion for attorneys' fees and reimbursement of expenses and Lead Plaintiff's requested Service Award, must be filed with the Court and delivered to Class Counsel and Defendants' Counsel such that they are received no later than August 8, 2022, in accordance with the instructions set forth in the Notice.
The issuance of this Notice is not an expression of any opinion by the Court concerning the merits of any claim in the Action, and the Court still has to decide whether to approve the Settlement. The Defendants deny the allegations of wrongdoing asserted in this Action, and deny any liability whatsoever to any member of the Class.
PLEASE DO NOT CONTACT THE COURT, THE CLERK'S OFFICE, DEFENDANTS, OR THEIR COUNSEL REGARDING THIS NOTICE. All questions about this notice, the Settlement, or your eligibility to participate in the Settlement should be directed to Class Counsel or the Claims Administrator.
BY ORDER OF THE COURT
United States District Court
Southern District of California
View original content:
SOURCE JND Legal Administration
|
https://www.wibw.com/prnewswire/2022/07/08/summary-notice-proposed-class-action-settlement-involving-bofi-holding-inc-common-stock-call-options-put-options/
| 2022-07-08T14:49:25 |
TAICHUNG, Taiwan, July 11, 2022 /PRNewswire/ -- Globe Union Industrial Corp., the parent company of the U.S.-based Gerber Plumbing Fixtures, announces that its faucet manufacturing in Fuyong, Shenzhen, China, will be moved to a facility located in Machong, Guangdong, China. This decision is a result of plans made by the district government of Shenzhen to urbanize the area around Globe Union's faucet manufacturing facility, which include a road that will be built directly through the Company's current Fuyong facility.
This new manufacturing site will focus on the business's core manufacturing competencies, while leveraging its supply chain partners' strengths and efficiencies. The transition will take place over the next 15 months in alignment with the timeline provided by the local government in Shenzhen.
Headquartered in Taichung, Taiwan, Globe Union is a worldwide leader in kitchen and bathroom plumbing products. Globe Union has five key brands, including Gerber Plumbing Fixtures. Globe Union's commitment to excellence is embodied by offering customers the best possible value for the highest standards of product design and manufacture.
For nearly a century, Gerber has manufactured tried and true, high-quality kitchen and bathroom plumbing products. Each team member in the Gerber family delivers on our commitment to providing dependability reflected in both our products and customer care throughout North America. We earn the trust of trade professionals and homeowners alike who find value in products that have both style and substance – performing without exception for years to come, all while being surprisingly affordable. Gerber's comprehensive offering of plumbing solutions is created with the entire experience in mind, from easy installation to reliable everyday use, and is supported by Gerber's industry-leading warranties. As a partner in the U.S. EPA WaterSense® Program, Gerber is committed to protecting the environment through resource conservation, and creating high-efficiency and eco-friendly products.
View original content to download multimedia:
SOURCE Globe Union Industrial Corp.
|
https://www.wibw.com/prnewswire/2022/07/11/globe-union-announces-move-manufacturing-facilities-due-local-chinese-government-urban-development-plans/
| 2022-07-11T11:33:46 |
NEW YORK, June 1, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ironnet, Inc..
Shareholders who purchased shares of IRNT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
CLASS PERIOD: September 15, 2021 to December 15, 2021
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company had materially overstated its business and financial prospects; (ii) the Company was unable to predict the timing of significant customer opportunities which constituted a substantial portion of its publicly- issued FY 2022 financial guidance; (iii) the Company had not established effective disclosure controls and procedures to reasonably ensure its public disclosures were timely, accurate, complete, and not otherwise misleading; and (iv) as a result, the Company's public statements were materially false, misleading, and/or lacked any reasonable basis in fact at all relevant times.
DEADLINE: June 21, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/ironnet-inc-loss-submission-form/?id=27904&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IRNT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 21, 2022. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
View original content:
SOURCE The Gross Law Firm
|
https://www.kxii.com/prnewswire/2022/06/01/shareholder-alert-gross-law-firm-notifies-shareholders-ironnet-inc-class-action-lawsuit-lead-plaintiff-deadline-june-21-2022-nyse-irnt/
| 2022-06-01T10:24:56 |
DALLAS (KDAF) — Summer is coming to a close soon, but not without a bang. Old City Park is celebrating the end of the summer with some style.
This iconic Dallas park will be hosting some fun events to close out the summer, throughout the month of August. Here’s all the fun they have in store:
- Bigger than Budweiser: Adolphus Busch’s Investments in the Lone Star State: Join us for a free reception in Old City Park’s Browder Springs Building, followed by a talk given by Dr. Todd Barnett from Trinity University. Dr. Barnett will be shedding light on the complexities of Busch’s business operations in Texas, and how rising populist, nativist, and prohibitionist sentiments affected Busch’s career in Texas.
- When: Thursday, August 18
- 6:00-6:30p.m. – Opening Reception; wine and snacks provided
- 6:30-7:30p.m. – Dr. Todd Barnett presentation.
- Foodies of America Festival: Join us for a pop up food truck festival featuring 10+ food trucks, live entertainment, retail vendors and more!
- When: August 27-28, 10:00a.m. – 4:00p.m.
|
https://cw33.com/news/local/celebrate-the-end-of-summer-with-these-fun-events-at-dallas-old-city-park/
| 2022-08-03T18:44:28 |
Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's® 82nd Scientific Sessions® and simultaneously published in NEJM
INDIANAPOLIS, June 4, 2022 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published today in The New England Journal of Medicine (NEJM) and presented in a symposium sponsored by the American Diabetes Association® (ADA) during the ADA's 82nd Scientific Sessions®. Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimandsi.
For the efficacy estimandii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo.
All three doses of tirzepatide achieved all key secondary endpoints at 72 weeks of treatment for the efficacy estimand, including:
- Percentage of participants achieving at least 10% body weight reductions: 73% (5 mg, not controlled for type 1 error), 86% (10 mg) and 90% (15 mg) compared to 14% with placebo.
- Percentage of participants achieving at least 15% body weight reductions: 50% (5 mg, not controlled for type 1 error), 74% (10 mg) and 78% (15 mg) compared to 6.0% with placebo.
- Percentage of participants achieving at least 20% body weight reductions: 32% (5 mg, not controlled for type 1 error), 55% (10 mg) and 63% (15 mg) compared to 1.3% with placebo.
- Change in waist circumference from baseline: -14.6 cm (5 mg, not controlled for type 1 error), ‑19.4 cm (10 mg) and -19.9 cm (15 mg) compared to -3.4 cm with placebo.
All three doses of tirzepatide achieved an additional secondary endpoint at 72 weeks of treatment, measuring the percentage of participants achieving at least 25% body weight reductions (not controlled for type 1 error): 16.5% (5 mg), 35% (10 mg) and 39.7% (15 mg) compared to 0.3% with placebo.
Participants taking tirzepatide also achieved an approximately three times greater percent reduction in fat mass versus lean mass (33.9% fat mass reduction compared to a 10.9% lean mass reduction).
"Obesity is a chronic, treatable disease, and individuals living with obesity deserve effective and safe treatment options that can help restore their weight to levels that support optimal health," said Ania Jastreboff, MD, Ph.D., Associate Professor of Medicine & Pediatrics, Endocrinology & Metabolism, at Yale School of Medicine; Director, Weight Management & Obesity Prevention at the Yale Stress Center; and co-Director of the Yale Center for Weight Management. "In SURMOUNT-1, participants taking tirzepatide on average lost up to one fifth of their body weight – and notably, about nine out of ten participants taking tirzepatide lost weight. These results are significantly higher than the placebo arm and underscore the importance of this study."
Tirzepatide also met the co-primary and all key secondary endpoints for the treatment-regimen estimandiii, including:
- Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared to 3.1% with placebo.
- Percentage of participants achieving body weight reductions of ≥5%: 85% (5 mg), 89% (10 mg) and 91% (15 mg) compared to 35% with placebo.
- Percentage of participants achieving ≥10% body weight reductions: 69% (5 mg, not controlled for type 1 error), 78% (10 mg) and 84% (15 mg) compared to 19% with placebo.
- Percentage of participants achieving ≥15% body weight reductions: 48% (5 mg, not controlled for type 1 error), 67% (10 mg) and 71% (15 mg) compared to 9% with placebo.
- Percentage of participants achieving body weight reductions of ≥20%: 30% (5 mg, not controlled for type 1 error), 50% (10 mg), and 57% (15 mg) compared to 3.1% with placebo.
- Change in waist circumference from baseline: -14.0 cm (5 mg, not controlled for type 1 error), ‑17.7 cm (10 mg) and -18.5 cm (15 mg) compared to -4.0 cm with placebo.
- Percentage of participants taking tirzepatide achieving ≥25% body weight reductions (not controlled for type 1 error): 15.3% (5 mg), 32.3% (10 mg) and 36.2% (15 mg) compared to 1.5% with placebo.
"Lilly is proud to share the detailed results from SURMOUNT-1, which reinforce our confidence in the potential of tirzepatide as a treatment for obesity, as participants lost between an average of 35 and 52 pounds throughout the trial," said Mike Mason, president, Lilly Diabetes. "Lilly aims to transform how diseases like obesity are understood and treated, and today's simultaneous publication and presentation of these results mark an important milestone in our mission."
The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies approved for the treatment of obesity. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity, usually occurring during the dose escalation period. For those treated with tirzepatide (5 mg, 10 mg and 15 mg, respectively), nausea (24.6%, 33.3%, 31.0%), diarrhea (18.7%, 21.2%, 23.0%), constipation (16.8%, 17.1%, 11.7%), and vomiting (8.3%, 10.7%, 12.2%) were more frequently experienced compared to placebo (9.5% [nausea], 7.3% [diarrhea], 5.8% [constipation], 1.7% [vomiting]).
Treatment discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) and 2.6% (placebo). The overall treatment discontinuation rates were 14.3% (5 mg), 16.4% (10 mg), 15.1% (15 mg) and 26.4% (placebo). The overall trial completion rates were 89% (5 mg), 88% (10 mg), 90% (15 mg) and 77% (placebo).
About SURMOUNT-1 and the SURMOUNT clinical trial program
SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S., Argentina, Brazil, China, India, Japan, Mexico, Russia and Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. Participants who had pre-diabetes at study commencement will remain enrolled in SURMOUNT-1 for an additional 104 weeks of treatment following the initial 72-week completion date to evaluate the impact on body weight and potential differences in progression to type 2 diabetes at three years of treatment with tirzepatide compared to placebo.
All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg).
The SURMOUNT phase 3 global clinical development program for tirzepatide began in late 2019 and has enrolled more than 5,000 people with obesity or overweight across six clinical trials, four of which are global studies. Results from SURMOUNT-2, -3, and -4 are anticipated in 2023.
Ania Jastreboff, MD, PhD conducts multi-center trials with Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals; serves on scientific advisory boards for Eli Lilly, Intellihealth, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, and WW (formerly WeightWatchers); and consults for Boehringer Ingelheim and Scholar Rock.
About tirzepatide
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is under regulatory review in Europe, Japan and several additional countries for the treatment of type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA), in chronic kidney disease and in morbidity/mortality in obesity are planned as well.
Tirzepatide was approved as Mounjaro™ (tirzepatide) by the FDA on May 13, 2022. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- Has not been studied in patients with a history of pancreatitis
- Is not indicated for use in patients with type 1 diabetes mellitus
Important Safety Information for Mounjaro™ (tirzepatide)
WARNING: RISK OF THYROID C-CELL TUMORS
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro.
Risk of Thyroid C-cell Tumors: Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. Pancreatitis has been reported in Mounjaro clinical trials. Mounjaro has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on Mounjaro. Observe patients for signs and symptoms, including persistent severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Hypersensitivity Reactions: Hypersensitivity reactions, sometimes severe, have been reported with Mounjaro in clinical trials. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.
Acute Kidney Injury: Mounjaro has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which if severe could cause acute kidney injury. In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, sometimes requiring hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Mounjaro in patients with renal impairment reporting severe adverse gastrointestinal reactions.
Severe Gastrointestinal Disease: Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. Mounjaro has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Acute Gallbladder Disease: In clinical trials, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
The most common adverse reactions reported in ≥5% of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
Drug Interactions: When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.
Pregnancy: Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.
Lactation: There are no data on the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.
Females of Reproductive Potential: Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.
Pediatric Use: Safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 18 years of age.
Please click to access Prescribing Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer, and Medication Guide.
Please see Instructions for Use included with the pen.
TR HCP ISI MAY2022
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. P-LLY
Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes, tirzepatide as a potential treatment for adults with obesity or overweight and the timeline for future readouts, presentations and other milestones relating to tirzepatide and its clinical trials, and reflects Lilly's current belief and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research development and commercialization. Among other things, there can be no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with the results to date, that tirzepatide will receive additional regulatory approvals, or that Mounjaro will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
i Treatment differences for two estimands – efficacy and treatment-regimen – were evaluated for three tirzepatide doses (5 mg, 10 mg and 15 mg) compared to placebo.
ii Efficacy estimand represents efficacy prior to discontinuation of study drug.
iii Treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation.
Refer to:
Maggie Pfeiffer; [email protected]; 317-650-5939 (Media)
Kevin Hern; [email protected]; 317-277-1838 (Investors)
View original content to download multimedia:
SOURCE Eli Lilly and Company
|
https://www.wibw.com/prnewswire/2022/06/04/lillys-surmount-1-results-published-new-england-journal-medicine-show-tirzepatide-achieved-between-160-225-weight-loss-adults-with-obesity-or-overweight/
| 2022-06-04T14:21:04 |
WASHINGTON, June 1, 2022 /PRNewswire/ -- The American College of Emergency Physicians (ACEP) is pleased to announce that Donald M. Yealy, MD, FACEP, is the new editor in chief for Annals of Emergency Medicine.
In this role, Dr. Yealy will oversee the largest and most frequently cited peer-reviewed journal in emergency medicine. He brings decades of expertise in research and scientific process, editing and communications.
"I am incredibly grateful for the opportunity to lead this distinguished publication," said Dr. Yealy. "Trusted medical research is the foundation for innovation that can change the practice of emergency medicine and save lives. I look forward to working with authors, editors, and readers to guide the data and dialogue that will propel emergency medicine forward for years to come."
Dr. Yealy joined the Annals of Emergency Medicine editorial board in 1997 and became deputy editor in 2006. He is a distinguished professor and chair of the Department of Emergency Medicine at the University of Pittsburgh, and chief medical officer and senior vice president of the University of Pittsburgh Medical Center. He is a member of the National Academy of Medicine and a prolific scientific author and evaluator of grant and manuscript submissions.
Dr. Yealy's areas of focus have included optimal airway management, predictive risk modeling, and emergency care for patients with critical illness. He has been published more than 400 times, including as lead or senior author on National Institutes of Health (NIH) efforts in acute pneumonia, pulmonary embolism, and sepsis care.
Dr. Yealy assumes his duties following the retirement of Michael L. Callaham, MD, who held the role for 20 years and leaves an indelible impact on the journal and the specialty.
Dr. Callaham began working with the Annals editorial team in 1982. Through his tenure, he conducted and published seminal works on editorial techniques, took on the challenge of modernizing the peer-review process, and moved Annals from paper review methods to an electronic editorial process. Under Dr. Callaham's leadership, Annals became the top journal in emergency medicine.
"Emergency physicians are at the core of solutions to many of the major public health challenges of our time," said Gillian Schmitz, MD, FACEP, president of ACEP. "Dr. Yealy's experience and vision will undoubtedly serve Annals of Emergency Medicine and its readers well as the journal strengthens its position as a leader in groundbreaking research and critical analysis in emergency medicine."
Annals of Emergency Medicine is one of the peer-reviewed scientific journals for the American College of Emergency Physicians (ACEP), the national medical society representing emergency medicine. Annals of Emergency Medicine is the largest and most frequently cited circulation peer-reviewed journal in emergency medicine and publishes original research, clinical reports, opinion, and educational information related to the practice, teaching, and research of emergency medicine.
View original content to download multimedia:
SOURCE American College of Emergency Physicians (ACEP)
|
https://www.kxii.com/prnewswire/2022/06/01/acep-announces-new-editor-chief-annals-emergency-medicine/
| 2022-06-01T18:32:49 |
BERRYVILLE, Va., June 1, 2022 /PRNewswire/ -- Bank of Clarke County, a wholly-owned subsidiary of Eagle Financial Services, Inc., whose divisions include Eagle Investment Group, announced that Joseph (Joe) T. Zmitrovich has been appointed President and Chief Banking Officer for the Bank. In this new position, Joe will head up merger and acquisition strategy to ensure full engagement in acquisition plans related to individual branch expansion, niche business acquisition, and whole bank purchases, while continuing his oversight of commercial lending, retail banking, cash management, loan operations and loan servicing.
Mr. Zmitrovich joined the Bank in 2016 as its Senior Vice President and Lending Officer. In 2019, Joe was promoted to Executive Vice President and Chief Revenue Officer and in 2021, to Executive Vice President and Chief Banking Officer. Mr. Zmitrovich has over 29 years of banking experience and prior to joining the Bank, Joe served as Market President of the Southern Pennsylvania region for BB&T from 2015 to July 2016. From 2008 to 2015 he served as Senior Vice President and Commercial Executive for Susquehanna Bank.
Mr. Zmitrovich currently serves on the Boards of the Loudoun County Chamber and Bankers Title Shenandoah.
Brandon Lorey, Bank of Clarke County CEO, stated "Given the increased complexity of our organization, this was a natural next step for both the Bank and for Joe. I am thrilled to leverage Joe's background and expertise in mergers and acquisitions as we continue to look for acquisition opportunities, grow organically, and enhance shareholder value."
Eagle Financial Services, Inc. is a bank holding company which wholly owns Bank of Clarke County (the "Bank"). The Bank offers a wide range of retail and commercial banking services, including demand, savings, and time deposits and consumer and commercial loans. The Bank also offers both a trust department and investment services and has 13 full-service branches, two loan production offices, and one drive-through only facility. The Bank serves Northern Virginia and the Shenandoah Valley area, with branches located in Clarke County, Frederick County VA, Loudon County, Fairfax County, Frederick County MD, and the Towns of Leesburg, Purcellville, and Warrenton, and the City of Winchester.
View original content to download multimedia:
SOURCE Bank of Clarke County
|
https://www.mysuncoast.com/prnewswire/2022/06/01/zmitrovich-named-bank-president-chief-banking-officer-bank-clarke-county/
| 2022-06-01T20:01:03 |
Colorado governor signs bill to protect access to abortion
By Shawna Mizelle and Amy Simonson, CNN
Colorado Democratic Gov. Jared Polis signed a bill into law on Monday that codifies the right to an abortion in the state.
House Bill 1279, the Reproductive Health Equity Act, states that “every individual has a fundamental right to make decisions about the individual’s reproductive health care, including the fundamental right to use or refuse contraception; a pregnant individual has a fundamental right to continue a pregnancy and give birth or to have an abortion and to make decisions about how to exercise that right; and a fertilized egg, embryo, or fetus does not have independent or derivative rights under the laws of the state.”
Polis’ signature follows a flurry of recent restrictive abortion laws advanced by Republican state legislatures across the country.
The bill, which passed in the state’s Democratic-majority House and Senate last month on party-line votes, also prohibits local entities from implementing their own restrictions.
“In the State of Colorado, the serious decision to start or end a pregnancy with medical assistance will remain between a person, their doctor, and their faith,” Polis said in a statement on Monday.
The governor emphasized that the new law “does not make any changes to the current legal framework,” saying: “This bill simply maintains this status quo regardless of what happens at the federal level and preserves all existing constitutional rights and obligations.”
The US Supreme Court appears poised to uphold a Mississippi law that bars abortion after 15 weeks. The fate of Roe v. Wade, the landmark 1973 Supreme Court decision that legalized abortion nationwide, also hangs in the balance, and anti-abortion activists are hopeful that the court’s conservative majority will strike it down.
Florida, West Virginia, Kentucky and Arizona have all moved on 15-week abortion bans this session. And Idaho has imposed a six-week abortion ban, which was the first such bill signed into law this year that mimics a controversial Texas law.
Colorado House Majority Leader Daneya Esgar, a sponsor of the bill, said in a statement that “enshrining the right to choose when it comes to reproductive health care, including the right to abortion, shows we trust Coloradans to make their own medical decisions.”
The-CNN-Wire
™ & © 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.
|
https://localnews8.com/politics/cnn-us-politics/2022/04/04/colorado-governor-signs-bill-to-protect-access-to-abortion/
| 2022-04-05T03:12:18 |
Is the Solo Stove Bonfire 2.0 Fire Pit worth it?
There’s nothing quite like sitting around a fire pit. It creates an atmosphere that brings people together, invites exchanges and creates memories. However, unless you’re having a backyard picnic, fire pits can be cumbersome to transport, and the smoke can sting your eyes whenever the wind changes, while the odor can linger in your clothes.
Solo Stove has a solution. The company’s Bonfire 2.0 is a fire pit that’s engineered with a 360-degree airflow that “super-heats air to burn off smoke before it can get to your clothes and hair.” It’s easy to set up and weighs approximately 23 pounds, so it’s highly portable.
We wanted to see if the Solo Stove Bonfire 2.0 Fire Pit was really as effortless to use as the company claimed, so we decided to test it. Here’s what we found.
Testing the Solo Stove Bonfire 2.0 Fire Pit
Growing up, our tester was a scout. They camped out often and spent many nights and weekends around a campfire or camping stove. As an adult, our tester frequently entertains outdoors but uses a more traditional bowl-shaped fire pit. They were very interested in the smokeless feature and ease of setup and cleaning that the Bonfire 2.0 promised.
What is the Solo Stove Bonfire 2.0 Fire Pit?
The Bonfire 2.0 is a modern-looking fire pit that almost appears too fancy at first glance. It has a double-walled stainless steel construction and is shaped like a large can that’s 19.5 inches in diameter and 14 inches high. The fire pit only weighs 23.3 pounds and comes with a carry bag to make it easy to transport. It uses wood for fuel and has a signature airflow design that increases the burning efficiency to reduce smoke during use.
Solo Stove Bonfire 2.0 Fire Pit price and where to buy
While the MSRP for the Solo Stove Bonfire 2.0 Fire Pit is $399.99, it’s currently available for $344.99 on Amazon and $259.99 at Solo Stove.
How to use the Solo Stove Bonfire 2.0 Fire Pit
When we unboxed this unit, we found the main body, an ash pan, a bottom grate and a flame ring for the top. It was obvious how the pieces assembled, and we had it ready to use in about two minutes.
Once assembled, you must make sure the top piece, the flame ring, is facing upward to create optimum airflow. Choose kiln-dried or seasoned hardwood for your fire, because this will start and burn more easily as well as burn longer. Make sure you have kindling and fire starters on hand to make starting even easier and create an ember bed before adding larger pieces of wood to the fire pit. When adding firewood, make sure never to stack it above the air holes located at the top of the unit.
When we were starting the fire, we found there was a little smoke while the unit heated up. However, once the fire got going, the Bonfire 2.0 was virtually smoke-free. There’s a faint trace of smoke that you can detect when sitting downwind, but it wasn’t bothersome, in our opinion.
The big change from the previous version is that the Bonfire 2.0 has an ash pan. While this may seem like a minor upgrade, it really makes things a lot easier. With the old model, you had to wait for it to cool and then flip the entire unit upside-down to clean. Since this model weighs roughly 23 pounds, it can be a little awkward to do that. It’s even tougher with the largest model, the Yukon because it weighs over 40 pounds. With the Bonfire 2.0, however, you just lift up the bottom grate after the unit has completely cooled, remove the ash pan and dump. It makes cleaning nearly effortless.
Solo Stove Bonfire 2.0 Fire Pit benefits
The Solo Stove has many benefits over a traditional fire pit. It’s portable, easy to set up and produces a good amount of heat. The Bonfire 2.0 doesn’t create enough smoke to be troublesome — we hardly even noticed it. The temperature seems to be hotter than other fire pits, as there is very little ash remaining when the fire is done. Lastly, cleanup is easy. All you have to do is lift the grate, remove the ash pan and dump.
Solo Stove Bonfire 2.0 Fire Pit drawbacks
The biggest drawback to purchasing this impressive fire pit is the price. But on the plus side, you do get more for your money, so it’s still a solid value. Obviously, the fire pit gets hot during use, so just be careful and wait until it has completely cooled before emptying and packing it up for transport. All in all, though, there were no flaws that we discovered with the design or operation of this fire pit.
Should you get the Solo Stove Bonfire 2.0 Fire Pit?
If you have the budget and you want the best, the Solo Stove Bonfire 2.0 Fire Pit is worth every penny. Solo Stove has engineered a product that’s simply better than a normal fire pit. The low-smoke alone makes it more than worth the price.
Sold by Solo Stove
Other fire pits to consider
If you love Solo Stove but prefer something more portable, The Ranger 2.0 is just 15 inches in diameter and 12.5 inches high. This is the company’s smallest model, but it still has all the features of the larger sizes: smokeless fire, removable ash pan and efficient heating.
Sold by Solo Stove
If you prefer a larger fire pit, the Yukon is the company’s largest option. It’s 27 inches in diameter and 17 inches tall, making it a suitable gathering point for family and friends.
Sold by Solo Stove and Amazon
Sunnydaze Decor Folding Wood-Burning Fire Pit
Sunnydaze has a bowl-shaped fire pit with collapsible legs that comes with a carrying case. It weighs only 12 pounds, so it’s very portable and easy to store. The fire pit is made of steel and is finished with high-temperature paint. It also comes with a mesh spark screen and a poker.
Sold by Amazon and Home Depot
Endless Summer Gas Fire Pit with Electronic Ignition
If you prefer a more permanent model, this gas fire pit is a beautiful piece of furniture. It’s made with weather-resistant steel and the base elegantly hides the propane tank (not included) and control panel. The fire pit comes with lava rocks and requires no tools for assembly.
Sold by Amazon and Home Depot
Want to shop the best products at the best prices? Check out Daily Deals from BestReviews.
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Allen Foster writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved.
|
https://cw33.com/reviews/br/patio-br/fire-pits-heaters-br/the-solo-stove-2-0-series-has-an-ash-pan-to-improve-clean-up-on-the-wildly-popular-fire-pits-is-it-worth-it/
| 2022-08-05T13:18:50 |
CLIFTON, N.J., Aug. 30, 2022 /PRNewswire/ -- Inc. magazine revealed on August 9 their list of America's top 5,000 fastest growing private companies. Spruce Technology [Spruce], is ranked 131 in New Jersey, 378 in New York, and 368 in the IT services category on this esteemed list.
"The past couple of years have been challenging for businesses of all shapes and sizes. Successful companies have had to adapt to a new world of doing business and the changing needs of their clients. I am so proud of the wonderful work, and growth, Spruce has achieved during these times. This is a special honor that speaks volumes about our agility, company, culture, leadership, evolving services, and the people who make this all a reality: our employees. Their hard work, passion, and dedication is remarkable," said Srini Penumella, CEO of Spruce.
First introduced in 1982, the Inc. 5000 list today represents the top .07% of all privately owned companies in the United States and ranked by revenue percentage growth from 2018 to 2021. But what makes inclusion in this year's list most impressive are the rapid changes caused by the pandemic, unprecedented changing client needs, and challenging economic landscape.
"The key to our success is transparent leadership; truly understanding our client's IT challenges; hiring the best talent; and providing a culture and career growth to retain them. This recognition also would not be realized without the trust our clients place in us every day and the close relationships we have with our strategic partners. Spruce is excited about this honor and the future of our company," said Srini.
About Spruce Technology
Spruce Technology is a full-service information technology consulting firm providing cutting-edge solutions for our clients across the public and commercial sectors. Since 2006, Spruce has been solving problems by building scalable systems and fortifying security for clients around the world, combining intellect and ingenuity to drive progress. As a leader in delivering results through our multifaceted approach to IT consulting, Spruce specializes in areas such as cybersecurity, digital experiences, and data services. Visit us at SpruceTech.com
Contact: Kristen Mazza, [email protected]
View original content to download multimedia:
SOURCE Spruce Technology Inc
|
https://www.wibw.com/prnewswire/2022/08/30/spruce-technology-recognized-prestigious-inc-5000-list-fastest-growing-us-private-companies/
| 2022-08-30T15:54:48 |
41 arrested in ‘Sex Money Murder’ sting operation, including some from Polk County
SARASOTA, Fla. (WWSB) - Detectives with the Polk County Sheriff’s Office, Polk County Sheriff Grady Judd and Attorney General Ashley Moody announced the arrest of 41 members and associates of the “Sex Money Murder” criminal gang enterprise . Sheriff Judd also shared surveillance video of a drive-by shooting that investigators say is connected to gang activities.
The investigation was initiated in March of 2021 when, based on information obtained from historical on-going criminal investigations, detectives uncovered an extensive criminal network associated with the Sex Money Murder gang.
Out of the 41 identified during the investigation, 12 are charged with racketeering for their role in directing members in organized criminal activity, such as illegal drug sales, robberies, introduction of contraband into prisons, conspiracy to commit murder, and coordinated attacks on other gang members.
The RICO charges are first degree felonies punishable as a life felony based upon specific provisions. In some cases, criminal gang members were in the Florida state prison system or in the county jail conducting and coordinating gang business.
The 41 suspects are charged with a total of 121 felonies and 40 misdemeanors. The suspects’ previous criminal histories include 1,147 felonies, 161 misdemeanors, and 205 felony convictions; an average of 28 felonies, 4 misdemeanors, and 5 felony convictions each.
“All you need to know about this gang is in its title: Sex Money Murder. We are not going to put up with these gangs brazenly coordinating and committing crimes in our communities. They are an organized criminal enterprise, ruthlessly focused on violence, theft, fraud, and profiting from the human misery and violence of the illegal drug trade. Our message to other gang members in Polk County and throughout Florida: don’t throw your life away on gangs. If you do, we will catch you, and you will go to prison for a long, long time,”Grady Judd, Sheriff
The investigation has been able to identify the ranking structure and numerous members of the gang, operating both inside and outside of prison and in the county jail, in Polk County, in various other areas of the state of Florida, and in North Carolina. Detectives uncovered multiple instances of coordinating crimes, directing and coordinating gang activities, recruitment of new gang members, discussing bond payments, and gang financing, including setting and collecting gang dues.
Detectives served six search warrants throughout the investigation including Lakeland, Winter Haven, Mount Dora, Orlando, and Lake City.
Illegal drugs, firearms, and currency seized:
· 21.45 Pounds of Methamphetamine
· 2,595 grams of cocaine
· 3,051 grams of cannabis
· 249 grams of MDMA
· 719 grams of Synthetic Cannabis
· 7.86 grams of Fentanyl (one gram can kill hundreds)
· 28 grams of Mushrooms
· 8 grams of Alprazolam
· 52 grams of Oxycodone
· 1846 grams of Promethazine
· 18 firearms
· $17,514.00 in US currency
The total street value of the drugs confiscated is over $1.5 million.
Copyright 2022 WWSB. All rights reserved.
|
https://www.mysuncoast.com/2022/04/13/41-arrested-sex-money-murder-sting-operation-including-some-polk-county/
| 2022-04-15T09:54:46 |
BIRMINGHAM, Ala. (AP) — Two sisters who survived the Holocaust as girls and moved to the United States afterward died just days apart in their adopted home of Alabama.
The Alabama Holocaust Education Center said Ruth Scheuer Siegler died Saturday at the age of 95. Her sister, Ilse Scheuer Nathan, died 10 days earlier at the age of 98.
The women were born in Germany and were girls when Adolf Hitler rose to power in the 1930s. After losing their parents and older brother in the Holocaust but surviving Nazi death camps themselves, the two women were inseparable, the center said in an announcement.
“They were always together,” Ann Mollengarden, education director for the Alabama Holocaust Education Center, told Al.com. “When Ilse died, I think Ruth was ready.”
In early 1944, the girls were selected as workers at the Birkenau camp and separated from their mother, who they never saw again, according to a biography of the women. They last saw their father at the camp, and their brother died at a camp in Germany.
“The girls worked carrying bricks from one end of the compound to the other for hours at a time. Ilse sewed gun covers and uniforms as well. Working close to the crematory ovens, they saw the mountains of shoes. For the first time, they realized that their fellow prisoners were being killed and cremated,” the biography said.
Each woman married fellow Holocaust survivors in 1949. Ruth and Walter Siegler moved to Birmingham in 1960 to be with Ilse and Walter Nathan, who already lived in the area.
The women, who taught lessons about the Holocaust, were both widows and remained best friends until the end, living within walking distance of each other for years.
In a 2011 interview with The Birmingham News, Ruth Siegler discussed the reasons for writing a memoir, “My Father’s Blessing,” which included papers and photographs that documented her journey surviving the Holocaust.
‘’I have all these memories,’’ she said. ‘’I remember everything.’’
During the interview, her sister Ilse came to visit. The sisters helped each other survive, and faith helped them through, they agreed.
‘’I always say have faith and hope,’’ Ilse Nathan said. ‘’We leaned on each other and prayed together.’’
|
https://cw33.com/news/nexstar-media-wire/alabama-sisters-who-survived-holocaust-die-just-days-apart/
| 2022-09-07T16:15:30 |
IRVING, Texas, Sept. 15, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Russ Denton has joined the company as Senior Vice President, General Counsel and Secretary, and will lead Caris' legal and corporate governance efforts.
Prior to joining Caris, Mr. Denton was a partner at Shearman & Sterling LLP, representing clients in mergers and acquisitions and equity financing transactions, including working with Caris as outside counsel in connection with Caris' growth equity financing transactions. Before his time at Shearman & Sterling, Mr. Denton was a partner at Andrews Kurth Kenyon LLP and an associate at Skadden, Arps, Slate, Meagher and Flom LLP.
"Caris is leading a revolution in healthcare with novel approaches to categorize, visualize and target disease in ways never before possible," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We are very pleased to welcome Russ to the Caris team, as his strong guidance and counsel has served us well, and will be invaluable as we continue to advance our mission."
"I am thrilled to join Caris and work for a company on the cutting edge of healthcare," said Denton. "I look forward to continuing to help support Caris and its mission."
Mr. Denton received his J.D. from Stanford Law School, and earned his B.S., magna cum laude, from Duke University.
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Caris Life Sciences Media Contact:
Lisa Burgner
[email protected]
214.294.5606
View original content to download multimedia:
SOURCE Caris Life Sciences
|
https://www.kxii.com/prnewswire/2022/09/15/caris-life-sciences-announces-appointment-russ-denton-general-counsel/
| 2022-09-15T11:51:03 |
System designed to enhance procedural safety in abdominal cavity during gynecological procedures; Integrated guard provides greater protection around surgical incision¹
CENTER VALLEY, Pa., Sept. 14, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the market launch of the Guardenia™ Contained Extraction System. Guardenia is the latest innovation in their contained tissue extraction product portfolio for gynecological procedures and is manufactured by Advanced Surgical Concepts (ASC) Ltd. of Bray, Ireland. Olympus America Inc. is the exclusive U.S. distributor of the system, which is indicated to contain and isolate tissue during, or prior to, surgical removal and/or extracorporeal manual morcellation.
The Guardenia system is designed to prevent the escape of cells into the abdominal cavity during extracorporeal manual morcellation, and its integrated guard provides protection against inadvertent damage from sharp surgical instruments around the incision. The guard offers superior incision retraction and protects a greater area of the containment element when compared to currently marketed devices.1
"Olympus is very pleased to continue its successful partnership with Advanced Surgical Concepts to provide innovative gynecological products for women's health care in the U.S.," said Richard Reynolds, President, Medical Systems Group, Olympus Corporation of the Americas. "Advancements in treatments such as contained tissue extraction help keep patients safe and can improve surgical outcomes, both of which are important aims of healthcare, while allowing surgeons to approach procedures with as minimally invasive an approach as possible."
"The Guardenia device offers a new standard of care for the patient through its novel technology," states Frank Bonadio CEO of ASC. "We're pleased to work with Olympus to launch the device."
Guardenia™ maximizes the amount of available space in the incision during a procedure by encroaching less into the incision and maintaining a stable protective area to complete manual tissue morcellation. Once in place, the design of the containment bag and guard ensures more durable protection of the specimen bag and the incision as compared to other marketed devices.¹
Protection of the integrity of the specimen bag is one of the critical design features of the Guardenia device. Guardenia's design securely anchors the guard and prevents bag dislodgement.¹
Other features of Guardenia include:
- Can be deployed through a standard 12mm trocar, under pneumoperitoneum and with or without vision;¹
- Guardenia is universal, and one size fits all;¹
- The guard automatically conforms to the shape and size of the incision to provide maximal protection of the containment bag;¹
- The guard is securely anchored in the incision and cannot become dislodged during tissue extraction;¹
- Employs "Set and forget" technology, allowing the surgeon to focus on the process of morcellation;¹
- Superior retraction of the incision, maximizing the working area for more ergonomic morcellation;1
- Maximizes the ratio of incision size to extraction opening;¹
- Bag material is designed to be impermeable to the passage of liquid or tissue, measured down to the cellular level;¹
- The device works across multiport, robotic and single-port surgery;¹
- No additional training is necessary.¹
Potential complications associated with the use of the Guardenia device are the same as those associated with the use of tissue or specimen bags, morcellation and laparoscopic surgery in general and include but are not limited to superficial lesions, injury to internal vessels, bleeding, hematoma, injury to the abdominal wall, injury to bowel, infection, peritonitis and spread of benign or malignant tissue.
For more information, visit the Guardenia™ Contained Extraction System product page.
Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit medical.olympusamerica.com.
Advanced Surgical Concepts (ASC) works closely with surgeons and specialist clinicians to conceive of new approaches to performing surgeries. In so doing, ASC designs and develops new medical devices to standardize the methods by which particular surgeries or diagnostic procedures will be performed. For more information, visit ASC at advancedsurgical.ie.
1 Data on file with ASC and Olympus 9/17/2021
View original content to download multimedia:
SOURCE Olympus
|
https://www.wibw.com/prnewswire/2022/09/14/olympus-launches-new-gynecology-contained-extraction-system-manual-tissue-morcellation/
| 2022-09-14T16:32:03 |
HOW GENETIC TESTING CAN PLAY A PIVOTAL ROLE IN BECOMING CANCER-FREE
June is National Cancer Survivors Month
SAN FRANCISCO, June 13, 2022 /PRNewswire/ --
BACKGROUND:
According to the National Cancer Institute, there were an estimated 16.9 million cancer survivors as of January 2019 in the United States. That number is projected to increase to 22.2 million by 2030. As June marks National Cancer Survivors Month, it's a time to celebrate the fact that life after a cancer diagnosis is a reality… a reality for over 16 million Americans.
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9043351-invitae-lyndsay-levingston-discuss-role-of-genetic-testing-during-cancer-survivors-month/
BREAST CANCER SURVIVOR'S STORY
In July 2019, Lyndsay Levingston was only 37 years old leading a successful career in NYC as a TV news personality when she discovered a lump in her right breast. She was diagnosed with Stage 2B triple-negative breast cancer and was given an immediate treatment plan. About halfway through her chemo journey, Lyndsay decided to take a medical genetic test from Invitae and the results prompted Lyndsay's doctor to completely change her surgical plan. The reasoning? Her genetic test revealed that she carries the BRCA1 mutation, which is known to increase the risk of breast and ovarian cancers. Like many others, Lyndsay assumed that genetic testing was only done to find risks – not necessarily inform treatment. On February 14, 2020, her doctor called to let her know she was in remission. She's been cancer-free since that call and through her organization SurviveHER™, she has continued to advocate for all women, especially other Black women (who according to the CDC, are 40% more likely to die from breast cancer) to prioritize their health and consider medical genetic testing as a proactive measure. In fact, she recently penned a piece for Essence.com for National Minority Health Month emphasizing the importance of genetic testing.
MEDIA SPOTLIGHT / INTERVIEW TOPIC
Lyndsay shares her powerful story about surviving breast cancer and the importance of genetic testing in both assessing risks and determining treatment options.
DID YOU KNOW?
- Medical genetic testing is equally important for patients already navigating breast or other types of cancer.
- Changes in treatment after an oncologist reviews medical genetic testing results aren't uncommon. In fact, research shows that risk-causing genetic changes are common across cancer types and when patients do receive genetic testing, the majority are eligible for changes to their treatment plans.
- BRCA1 and BRCA2 are the most common genes known to increase the risk of breast and ovarian cancers.
MORE ABOUT LYNDSAY LEVINGSTON
Lyndsay is an experienced multimedia maven and communications professional having worked in various capacities including anchor, host, reporter and producer for the Black News Channel, New York's Verizon Fios1, New York 1 News, KPRC Channel 2 Houston, FOX 26 Houston, NTV Houston and FOX Tulsa. Lyndsay's portfolio also includes work as a media and public relations consultant for organizations, businesses, and politicians. The multi-hyphenate is a Houston native who lends her talents to various community, corporate and social engagements as emcee, moderator and speaker. Lyndsay is an active member of Alpha Kappa Alpha Sorority, Inc. – Mu Kappa Omega Chapter in Missouri City and the Junior League of Houston. She graduated with honors from the University of North Texas with a Bachelor of Arts in Communication Studies, and dual minors in dance and secondary education. Lyndsay was diagnosed with Stage 2B triple-negative breast cancer in July 2019. She celebrates her cancer-free status as the founder of SurviveHER™, a breast cancer awareness and wellness nonprofit whose mission is to inform, inspire and empower women. Her story of victory has been featured on Essence.com, OprahMag.com, NBC National News, Ch. 2 and KHOU 11. CORE Magazine named Lyndsay to its inaugural "100 Most Influential Blacks Today" list in 2021.
Provided by: Invitae (pronounced in-VEE-tay)
View original content:
SOURCE Invitae
|
https://www.kxii.com/prnewswire/2022/06/13/surviveher-founder-multimedia-personality-lyndsay-levingston-shares-her-powerful-story-breast-cancer-survivor/
| 2022-06-13T12:32:51 |
GUANGZHOU, China, Aug. 24, 2022 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced its unaudited financial results for the second quarter ended June 30, 2022 and the first half of 2022.
Second Quarter 2022 Operational and Financial Highlights
- Total loan origination volume[1] was RMB3,137.3 million (US$468.4 million) in the second quarter of 2022, compared to RMB3,824.5 million in the same period of 2021.
- Total outstanding loan principal[2] was RMB9,381.9 million (US$1,400.7 million) as of June 30, 2022, compared to RMB10,411.9 million as of December 31, 2021.
- Total interest and fees income was RMB410.6 million (US$61.3 million) in the second quarter of 2022, compared to RMB451.5 million in the same period of 2021.
- Net income was RMB18.1 million (US$2.7 million) in the second quarter of 2022, compared to RMB65.2 million in the same period of 2021.
- Basic earnings per ADS and diluted earnings per ADS were RMB0.27 (US$0.04) and RMB0.24 (US$0.04), respectively, in the second quarter of 2022, compared to RMB0.95 and RMB0.94, respectively, in the same period of 2021.
First Half of 2022 Operational and Financial Highlights
- Total loan origination volume[1] was RMB5,404.6 million (US$806.9 million) in the first half of 2022, compared to RMB6,666.2 million in the same period of 2021.
- Total interest and fees income was RMB828.0 million (US$123.6 million) in the first half of 2022, compared to RMB876.6 million in the same period of 2021.
- Net income was RMB61.2 million (US$9.1 million) in the first half of 2022, compared to net income of RMB150.9 million in the same period of 2021.
- Basic earnings per ADS and diluted earnings per ADS were RMB0.90 (US$0.13) and RMB0.80 (US$0.12), respectively, in the first half of 2022, compared to RMB2.20 and RMB2.17 respectively, in the same period of 2021.
Mr. Bin Zhai, Chairman and Chief Executive Officer of CNFinance, commented, "During the second quarter of 2022, we maintained stable business operations despite regional city lockdowns due to pandemic prevention and control measures. We originated loans of RMB3.1 billion under our collaboration with trust companies and introduced loans of RMB200 million to the commercial bank partners. In light of the strict local measures implemented to contain the COVID-19 pandemic as well as the uncertainties associated with China's real estate industry, we also recorded a provision for credit losses accordingly.
Going forward, we are likely to be continuously challenged by economic fluctuations. On the other hand, however, we are confident that as China's economic growth starts to recover, and more supportive policies toward MSEs take effect, we are presented with vast business opportunities. In order to serve more MSE owners and fulfill our mission to provide accessible, affordable and efficient financing solutions to micro- and small-enterprise owners in China, we will strive to expand our sales channels, diversify our product portfolio, reduce our funding costs, and improve post-loan management efficiency to help sales partners expand their business scale."
Second Quarter 2022 Financial Results
Total interest and fees income decreased by 9.1% to RMB410.6 million (US$61.3 million) for the second quarter of 2022 from RMB451.5 million in the same period of 2021.
Interest and financing service fees on loans decreased by 9.1% to RMB408.1 million(US$60.9million) for the second quarter of 2022 from RMB448.8 million in the same period of 2021, primarily due to the decrease of average daily outstanding loan principal in the second quarter of 2022 as compared to the same period of 2021. The decrease in average daily outstanding loan principal was due to the lower loan facilitation volume in the second quarter of 2022 resulted from the lockdowns due to local outbreaks of COVID-19 in multiple cities within China.
Interest on deposits with banks decreased by 7.4% to RMB2.5 million (US$0.4 million) for the second quarter of 2022 from RMB2.7 million in the same period of 2021, primarily due to smaller average daily balances of time deposits.
Interest and fees expenses decreased by 3.9% to RMB187.3 million (US$28.0 million) for the second quarter of 2022, compared to RMB195.0 million in the same period of 2021, primarily due to the decrease of principals of other borrowings.
Net interest and fees income was RMB223.3 million (US$33.3 million) for the second quarter of 2022, a decrease of 12.9% from RMB256.5 million in the same period of 2021.
Collaboration cost for sales partners decreased by 28.2% to RMB76.6 million (US$11.4 million) for the second quarter of 2022 from RMB106.7 million in the same period of 2021, primarily attributable to the lower fee rate the Company paid to the sales partners in the second quarter of 2022 as compared to the same period of 2021, resulted from the lower average effective interest rates of outstanding loans.
Net interest and fees income after collaboration cost was RMB146.7 million (US$21.9 million) for the second quarter of 2022, a decrease of 2.1% from RMB149.8 million in the same period of 2021.
Provision for credit losses increased by 439.5% to RMB79.3 million (US$11.8 million) for the second quarter of 2022 from RMB14.7 million in the same period of 2021. The increase was due to the increasing economic uncertainties caused by lockdowns in reaction to local outbreaks of COVID-19 as well as the downward pressure faced by China's real estate market during the second quarter of 2022.
Net gains on sales of loans increased by 98.3% to RMB23.6 million (US$3.5 million) for the second quarter of 2022 from RMB11.9 million in the same period of 2021 resulted from the increase of instalment payments fully made by sales partners who signed agreements to repurchase delinquent loans by instalments.
Other gains, net increased by 33.0% to RMB13.7 million (US$2.0 million) for the second quarter of 2022 from RMB10.3 million in the same period of 2021.
Total operating expenses increased by 4.6% to RMB91.4 million (US$13.6 million) for the second quarter of 2022, compared with RMB87.4 million in the same period of 2021.
Employee compensation and benefits decreased by 6.5% to RMB48.6 million (US$7.3 million) for the second quarter of 2022 from RMB52.0 million in the same period of 2021, primarily attributable to smaller incentives paid to the employees resulted from lower loan origination volume during the second quarter of 2022.
Share-based compensation expenses decreased by 68.1% to RMB1.5 million (US$0.2 million) for the second quarter of 2022 from RMB4.7 million in the same period of 2021. According to the Company's share option plan adopted on December 31, 2019, approximately 50%, 30% and 20% of the option granted will be vested on December 31, 2020, 2021 and 2022, respectively. Related compensation cost of the option grants will be recognized over the requisite period.
Taxes and surcharges increased by 7.1% to RMB9.0 million (US$1.3 million) for the second quarter of 2022 from RMB8.4 million for the same period of 2021, primarily attributable to an increase in the non-deductible value added tax ("VAT"). The increase in VAT was attributable to the characterization of certain amounts as "service fees charged to trust plans" which are a non-deductible item. According to the PRC tax regulations, "service fees charged to trust plans" incur a 6% VAT on the subsidiary level, but are not recorded as an input VAT on a consolidated trust plan level. "Service fees charged to trust plans" was increased in the second quarter of 2022 compared to the same period of 2021 due to newly established trust plans.
Operating lease cost decreased by 8.1% to RMB3.4 million (US$0.5 million) for the second quarter of 2022 as compared to RMB3.7 million for the same period of 2021, mainly due to the overall lowered leasing prices of commercial properties in some cities resulted from the local outbreaks of COVID-19 during the quarter.
Other expenses increased by 55.4% to RMB28.9 million (US$4.3 million) for the second quarter of 2022 from RMB18.6 million in the same period of 2021, primarily due to the increase in (a) attorneys' fees associated with legal proceeding of NPLs, and (b) fees paid to local channels for introducing sales partners to the Company in the second quarter of 2022.
Income tax expense decreased by 60.7% to RMB3.3 million (US$0.5 million) for the second quarter of 2022 from RMB8.4 million in the same period of 2021, primarily due to a decrease in the amount of taxable income.
Effective tax rate increased to 15.3% for the second quarter of 2022 from 11.4% in the same period of 2021, primarily due the decrease of proceeds of tax-free dividends from securities investment funds. Such proceeds were RMB1.0 million (US$0.2 million) in the second quarter of 2022 as compared to RMB42.9 million in the same period of 2021.
Net income decreased by 72.2% to RMB18.1 million (US$2.7 million) for the second quarter of 2022 from RMB65.2 million in the same period of 2021.
Basic earnings per ADS and diluted earnings per ADS were RMB0.27 (US$0.04) and RMB0.24 (US$0.04), respectively, in the second quarter of 2022, compared to RMB0.95 and RMB0.94, respectively, in the same period of 2021. One ADS represents 20 ordinary shares.
First Half of 2022 Financial Results
Total interest and fees income decreased by 5.5% to RMB828.0 million (US$123.6 million) in the first half of 2022 from RMB876.6 million in the same period of 2021, primarily due to a decrease in the Company's interest income on loans.
Interest and financing service fees on loans decreased by 5.5% to RMB822.7 million (US$122.8 million) in the first half of 2022 from RMB870.8 million in the same period of 2021, primarily due to the decrease of average daily outstanding loan principal in the first half of 2022 as compared to the same period of 2021. The decrease in average daily outstanding loan principal was due to the lower loan facilitation volume in the first half of 2022 resulted from the lockdowns due to local outbreaks of COVID-19 in multiple cities within China.
Interest on deposits with banks decreased by 8.6% to RMB5.3 million (US$0.8 million) in the first half of 2022 from RMB5.8 million in the same period of 2021, primarily due to smaller average daily balance of time deposits.
Interest and fees expenses increased by 10.5% to RMB388.2 million (US$58.0 million) in the first half of 2022 from RMB351.2 million in the same period in 2021, primarily due to the increase of the funding costs from trust companies.
Net interest and fees income was RMB439.8 million (US$65.6 million) for the first half of 2022, representing a decrease of 16.3% from RMB525.4 million in the same period of 2021.
Collaboration cost for sales partners decreased by 23.7% to RMB156.2 million (US$23.3 million) for the first half of 2022 from RMB204.8 million in the same period of 2021, primarily attributable to lower fee rate the Company paid to the sales partners in the first half of 2022 as compared to the same period of 2021, resulted from the lower average effective interest rates of outstanding loans.
Net interest and fees income after collaboration cost decreased by 11.5% to RMB283.6 million (US$42.3 million) for the first half of 2022 from RMB320.6 million in the same period of 2021.
Recovery/(Provision) for credit losses recorded a provision of RMB111.9 million (US$16.7 million) for the first half of 2022, compared to recovery of RMB2.5 million in the same period in 2021. The increase was due to the increasing economic uncertainties caused by lockdowns in reaction to local outbreaks of COVID-19 as well as the downward pressure faced by China's real estate market during the first half of 2022.
Net gains on sales of loans increased by 47.4% to RMB31.4 million (US$4.7 million) for the first half of 2022 from RMB21.3 million in the same period of 2021 resulted from the increase of instalments payments fully made by sales partners who signed agreements to repurchase delinquent loans by instalments.
Other gains, net increased by 74.6% to RMB31.6 million (US$4.7million) for the first half of 2022 from RMB18.1 million in the same period of 2021, primarily due to the increase of Credit Risk Mitigation Positions forfeited by the sales partners.
Total operating expenses decreased by 5.7% to RMB171.3 million (US$25.6 million) in the first half of 2022, compared with RMB181.6 million in the same period of 2021.
Employee compensation and benefits decreased by 9.3% to RMB91.6 million (US$13.7 million) in the first half of 2022 from RMB101.0 million in the same period in 2021, primarily attributable to smaller incentives paid to the employees resulted from lower loan origination volume during the first half of 2022.
Share-based compensation expenses decreased by 69.1% to RMB2.9 million (US$0.4 million) in the first half of 2022 from RMB9.4 million in the same period of 2021. According to the Company's share option plan adopted on December 31, 2019, approximately 50%, 30% and 20% of the option granted will be vested on December 31, 2020, 2021 and 2022, respectively. Related compensation cost of the option grants will be recognized over the requisite period.
Taxes and surcharges increased by 13.2% to RMB17.1 million (US$2.6 million) in the first half of 2022 from RMB15.1 million in the same period of 2021, primarily attributable to a increase in the non-deductible value added tax ("VAT"). The increase in VAT was attributable to the characterization of certain amounts as "service fees charged to trust plans" which are a non-deductible item. According to the PRC tax regulations, "service fees charged to trust plans" incur a 6% VAT on the subsidiary level, but are not recorded as an input VAT on a consolidated trust plan level. "Service fees charged to trust plans" was increased in the first half of 2022 compared to the same period of 2021 due to newly established trust plans.
Operating lease cost decreased by 10.3% to RMB7.0 million (US$1.0 million) for the first half of 2022 as compared to RMB7.8 million for the same period of 2021, mainly due to the overall lowered leasing prices of commercial properties in some cities resulted from the local outbreaks of COVID-19 in the first half of 2022.
Other expenses increased by 9.1% to RMB52.7 million (US$7.9 million) in the first half of 2022 from RMB48.3 million in the same period of 2021, primarily due to the increase in (a) attorneys' fees associated with legal proceeding of NPLs, and (b) fees paid to local channels for introducing sales partners to the Company.
Income tax expense was RMB18.7 million (US$2.8 million) in the first half of 2022, as compared to RMB37.6 million in the same period of 2021, primarily due to decrease in taxable income in the first half of 2022 as compared to the same period of 2021.
Effective tax rate increased to 23.4% for the first half of 2022 from 20.0% in the same period of 2021, primarily due the decrease of proceeds of tax-free dividends from securities investment funds. Such proceeds were RMB1.0 million (US$0.2 million) in the first half of 2022 as compared to RMB57.9 million in the same period of 2021.
Net income was RMB61.2 million (US$9.1 million) in the first half of 2022, as compared to RMB150.9 million in the same period of 2021.
Basic earnings per ADS and diluted earnings per ADS were RMB0.90 (US$0.13) and RMB0.80 (US$0.12), respectively, in the first half of 2022, compared to RMB2.20 and RMB2.17 respectively, in the same period of 2021. One ADS represents 20 ordinary shares.
As of June 30, 2022, the Company had cash and cash equivalents and restricted cash of RMB1.4 billion (US$0.2 billion), compared with RMB2.2 billion as of December 31, 2021, including RMB0.9 billion (US$0.1 billion) and RMB1.5 billion from structured funds as of June 30, 2022 and December 31, 2021, respectively, which could only be used to grant new loans and activities.
The delinquency ratio for loans originated by the Company increased from 24.1% as of December 31, 2021 to 25.4% as of June 30, 2022. Under the collaboration model, the delinquency ratio for first lien loans decreased from 29.1% as of December 31, 2021 to 29.0% as of June 30, 2022, and the delinquency ratio for second lien loans increased from 19.5% as of December 31, 2021 to 23.1% as of June 30, 2022. Under the traditional facilitation model, the delinquency ratio for first lien loans increased from 76.0% as of December 31, 2021 to 94.9% as of June 30, 2022, and the delinquency ratio for second lien loans increased from 75.8% as of December 31, 2021 to 100.0% as of June 30, 2022.
The delinquency ratio (excluding loans held for sale) for loans originated by the Company decreased from 16.2% as of December 31, 2021 to 14.9% as of June 30, 2022. Under the collaboration model, the delinquency ratio for first lien loans (excluding loans held for sale) decreased to 16.4% as of June 30, 2022 as compared to 18.9% as of December 31, 2021, and the delinquency ratio for second lien loans (excluding loans held for sale) increased from 14.1% as of December 31, 2021 to 14.6% as of June 30, 2022. Under the traditional facilitation model, the delinquency ratio for first lien loans (excluding loans held for sale) decreased from 49.7% as of December 31, 2021 to 27.9% as of June 30, 2022, and the outstanding balance of second lien loans under the traditional facilitation model as of June 30, 2022 was nil.
The NPL ratio for loans originated by the Company increased from 9.4% as of December 31, 2021 to 11.6% as of June 30, 2022. Under the collaboration model, the NPL ratio for first lien loans increased from 12.5% as of December 31, 2021 to 14.7% as of June 30, 2022, and the NPL ratio for second lien loans increased from 6.0% as of December 31, 2021 to 8.9% as of June 30, 2022. Under the traditional facilitation model, the NPL ratio for first lien loans increased from 59.2% as of December 31, 2021 to 94.9% as of June 30, 2022, and the NPL ratio for second lien loans increased from 64.2% as of December 31, 2021 to 97.2% as of June 30, 2022.
The NPL ratio (excluding loans held for sale) for loans originated by the Company decreased from 2.1% as of December 31, 2021 to 1.9% as of June 30, 2022. Under the collaboration model, the NPL ratio for first lien loans (excluding loans held for sale) decreased from 3.0% as of December 31, 2021 to 2.2% as of June 30, 2022, and the NPL ratio for second lien loans (excluding loans held for sale) was 1.7% as of June 30, 2022 as compared to 1.4% as of December 31, 2021. Under the traditional facilitation model, the NPL ratio for first lien loans (excluding loans held for sale) increased from 14.4% as of December 31, 2021 to 27.9% as of June 30, 2022, and the outstanding balance of second lien loans under the traditional facilitation model as of June 30, 2022 was nil.[3]
Recent Development
US$20 Million Share Repurchase Program
On March 16, 2022, the Company's board of directors authorized a share repurchase program under which the Company may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares (ADSs) during a period of up to 12 months commencing on March 16, 2022. As of June 30, 2022, the Company had repurchased an aggregate of approximately US$5.0 million worth of its ADSs under this share repurchase program.
Resignation of Directors
On August 23, 2022, the Company's Board of Directors accepted the resignation tendered by Mr. Ning Li and Mr. Peng Ge as directors of the Company, including any applicable board committee, effective immediately. Following their resignation, Mr. Li and Mr. Ge will not hold any position at the Company. The resignation of each of Mr. Li and Mr. Ge was due to personal reasons and changes in our shareholding structure, respectively, and each of them confirmed that he has no disagreement with the Board. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. Li and Mr. Ge for their contributions and services to the Company.
Business Outlook
The extent to which the COVID-19 pandemic impacts the Company's results of operations will depend on future developments of the pandemic in China and across the globe, which are subject to change and substantial uncertainty and therefore cannot be predicted. For the third quarter of 2022, based on the information available as of the date of this press release, we expect net income to be between RMB0 and RMB50 million.
The above outlook is based on the current market conditions and reflects our current and preliminary estimates of market and operating conditions, which are all subject to substantial uncertainty.
Conference Call
CNFinance's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on Wednesday, August 24, 2022 (8:00 PM Beijing/ Hong Kong Time on the same day).
Dial-in numbers for the live conference call are as follows:
A telephone replay of the call will be available after the conclusion of the conference call until 11:59 PM ET on August 31, 2022.
Dial-in numbers for the replay are as follows:
A live and archived webcast of the conference call will be available on the Investor Relations section of CNFinance's website at http://ir.cashchina.cn/.
Exchange Rate
The Company's business is primarily conducted in China and all of the revenues are denominated in Renminbi ("RMB"). This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.6981 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 30, 2022. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on June 30, 2022, or at any other rate.
Safe Harbor Statement
This press release contains forward-looking statements made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "confident" and similar statements. The Company may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: its goals and strategies, its ability to achieve and maintain profitability, its ability to retain existing borrowers and attract new borrowers, its ability to maintain and enhance the relationship and business collaboration with its trust company partners and to secure sufficient funding from them, the effectiveness of its risk assessment process and risk management system, its ability to maintain low delinquency ratios for loans it originated, fluctuations in general economic and business conditions in China, the impact and future development of COVID-19 pandemic in China and across the globe, and relevant government law, rules, policies or guidelines relating to the Company's corporate structure, business and industry. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.
About CNFinance Holdings Limited
CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company) is a leading home equity loan service provider in China. CNFinance conducts business by collaborating with sales partners and trust company partners. Sales partners are responsible for recommending micro- and small-enterprise ("MSE") owners with financing needs to the Company and the Company introduces eligible borrowers to its trust company partners who will then conduct their own risk assessments and make credit decisions. The Company's primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. The loans CNFinance facilitated are primarily funded through a trust lending model with its trust company partners who are well-established with sufficient funding sources and have licenses to engage in lending business nationwide. The Company's risk mitigation mechanism is embedded in the design of its loan products, supported by an integrated online and offline process focusing on risks of both borrowers and collateral and further enhanced by effective post-loan management procedures.
View original content:
SOURCE CNFinance Holdings Limited
|
https://www.wibw.com/prnewswire/2022/08/24/cnfinance-announces-second-quarter-first-half-2022-unaudited-financial-results/
| 2022-08-24T11:04:58 |
NEW YORK (AP) — Stocks fell broadly on Wall Street Wednesday, erasing most of their gains for the week, as investors were discouraged to see more evidence of inflation’s impact on businesses and another gloomy outlook on the global economy.
The losses follow several bumpy days for markets, with major indexes often lurching between gains and losses by the hour. The volatility persists as investors try to determine how rising interest rates and inflation will impact the economy.
The S&P 500 index fell 44.91 points, or 1.1%, to 4,115.77. The benchmark index managed to hold on to a slight gain for the week. It has notched losses for eight of the last nine weeks.
The Dow Jones Industrial Average fell 269.24 points, or 0.8%, to 32,910.90 and the Nasdaq fell 88.96 points, or 0.7%, to 12,086.27.
Banks and industrial companies were among the biggest weights on the broader market. Wells Fargo fell 1.8% and Union Pacific shed 3.1%. Some technology stocks also fell. Intel lost 5.3%.
Smaller company stocks fell more than the rest of the market. The Russell 2000 fell 28.56 points, or 1.5%, to 1,891.01.
Bond yields rose. The yield on the 10-year Treasury, which banks use to set rates on mortgages and other loans, rose to 3.02% from 2.97% late Tuesday.
The big concerns on Wall Street remain rising inflation and whether the Federal Reserve’s shift to aggressively raise interest rates will help temper the impact or possibly push the economy into a recession.
“What investors need to realize is it’s going to be a long time until inflation numbers look good,” said Brian Levitt, global market strategist at Invesco. “What they need to focus on is whether it gets better or worse related to expectations.”
Inflation continues to sting businesses. Lawn care products company Scotts Miracle-Gro slumped 8.9% after slashing its profit forecast for the year because retailers aren’t replenishing orders as expected. Retailers have been warning that inflation is crimping sales as consumers shift to either spending on services or focusing on necessities rather than purchasing otherwise discretionary items, like electronics.
The impact from inflation has only been worsened by Russia’s invasion of Ukraine, which has put more pressure on energy and food prices since February. U.S. crude oil prices rose 2.3% on Wednesday and are up 63% for the year, while wheat prices are up 39% in 2022. Supply chains have also gotten tighter following a series of lockdowns for Chinese cities fighting COVID-19 cases.
“As long as commodity prices remain elevated, its going to be more difficult to see headline inflation come down,” Levitt said.
Greater inflation pressure from the conflict in Ukraine and lockdowns in China prompted the Organization for Economic Cooperation and Development to cut its forecast for economic growth, following several other international groups, including the World Bank, that expect inflation to have a lingering impact on economies around the world.
Treasury Secretary Janet Yellen, testifying before the the Senate Finance Committee on Tuesday, said she expects inflation to remain elevated and bringing that down is a top priority. The Fed is widely expected to raise its key short-term interest rate by half a percentage point at its meeting next week. That would be the second straight increase of double the usual amount, and investors expect a third in July.
The Fed’s goal is to slow economic growth enough to cushion inflation’s impact. Demand for goods had been outpacing supplies and production capacity through most of the post-pandemic recovery. But, investors are concerned that the Fed could go too far too fast in raising rates and nudge the U.S. economy into a recession, especially with economic growth already slowing.
Wall Street is closely watching economic data for signals that could prompt the Fed to potentially ease up on the size of its rate increases. The next big update on inflation arrives Friday, when the U.S. government releases its latest reading on the consumer price index.
|
https://cw33.com/business/ap-business/asian-shares-mostly-higher-after-wobbly-rally-on-wall-st/
| 2022-06-08T23:32:26 |
JACKSON TOWNSHIP, N.J. , June 14, 2022 /PRNewswire/ -- The Jackson Township Council approved a resolution this evening to enter into a settlement agreement with the U.S. Department of Justice (DOJ) resolving the department's lawsuit alleging religious discrimination in the township's zoning practices. Under the terms of the settlement agreement, the township does not concede liability with respect to the claims alleged in DOJ's lawsuit and has committed to a series of actions to ensure compliance with all laws governing religious rights in land use and fair housing practices.
"This township council welcomes and embraces people of all faiths, races and ethnic backgrounds," said Mayor Michael Reina. "It's time for Jackson Township to move forward. This governing body is committed to ensuring that we will do just that in order to foster one, united community, respectful of all people who call Jackson home."
Specific details of the settlement will not be released until the agreement is fully executed by the DOJ and signed by the court. All land use changes introduced in the future will be subject to public review and comment before adoption. Settlement highlights, per the terms of the agreement with the DOJ, include the following actions, which the township is committed to undertaking. Jackson Township will:
- Ensure all land use regulations comply with federal and state laws, and will amend or introduce ordinances that permit schools with dormitories as an accessory to private, parochial and public schools in certain zoning districts;
- Provide notice about the township's active engagement in the settlement agreement, and about the requirements of the agreement, to its officers, elected and appointed officials, contractors, employees and agents, the public and all other interested parties;
- Provide training on the requirements of the settlement agreement, as well as the Fair Housing Act (FHA) and Religious Land Use and Institutionalized Persons Act (RLUIPA), to all township officers, elected and appointed officials, contractors, employees and agents whose duties relate to planning, zoning, permitting, construction, code enforcement and building occupancy;
- Submit reports to the DOJ detailing the township's compliance with terms of the settlement agreement, per agreed upon details and timelines for submission;
- Notify the DOJ about any amendments or modifications to the township's zoning code, rules, laws or ordinances that affect land uses for schools, residential schools, houses of worship or other religious uses;
- Retain all land use, law enforcement and associated records directly related to or coming from members of the Orthodox community;
- Allow for the inspections and copy of all non-privileged township records by the DOJ upon reasonable notice;
- Develop a written process to address complaints by any person who believes the township and/or any of its political subdivisions or departments may have violated religious and/or fair housing laws;
- Establish a settlement fund to be administered by the DOJ with all determinations made by the DOJ with funds totaling $150,000 for the purpose of compensating aggrieved persons who have suffered as a result of alleged discriminatory actions by the township; and provide notice to the public about the establishment of the fund;
- And finally, the township will pay a civil penalty of $45,000 to the DOJ as part of the settlement agreement.
The settlement agreement will remain in effect for a period of three years once executed by DOJ. Both the township and DOJ may seek to terminate parts of the agreement, or the entire agreement, prior to the expiration period if the township can demonstrate that it has established "full, effective and lasting compliance" with either parts of the agreement or the entire agreement. If, prior to the expiration of the settlement, the DOJ determines that the township has failed to satisfy the terms of the agreement, or the DOJ has reason to believe that violations of the FHA or RLUIPA are ongoing, the government may seek to extend the term of the settlement.
By entering into the settlement agreement, the township does not concede liability with respect to the claims alleged in DOJ's lawsuit, meaning the township does not admit any wrongdoing on behalf of the township or any of its officials.
"By settling this matter, the township retains control over its planning and zoning functions instead of running the risk of ceding control of those essential functions to the court," Mayor Reina said. "The settlement also gives us the opportunity to ensure that our planning and zoning framework complies with all controlling federal and state laws. And, very importantly, the settlement allows us to put an end to this costly and lengthy litigation."
The DOJ's Division of Civil Rights filed suit against Jackson Township on May 20, 2020. Since that time, township attorneys, in close consultation with the township council, have engaged in collaborative negotiations with the DOJ. Now that the township has agreed to the settlement, it will become effective once executed by the DOJ and signed by the court. Once in effect, the township will introduce revised land use ordinances, which will be subject to public review and comment before adoption. Specifics of the settlement agreement cannot be discussed publicly until it is fully executed.
Related legal actions in this matter, including a complaint filed by the Attorney General of New Jersey and, separately, by a private party, remain pending for the township.
About Jackson Township
Jackson Township is a growing, suburban community that offers an ideal environment for families and businesses to grow and prosper. Covering over 100 square miles, Jackson Township is the fourth largest municipality, as measured by area, in the state of New Jersey, and is home to just 60,000 residents. The township boasts an excellent public school system and first-rate recreational facilities, including newly renovated parks and athletic fields. Situated in beautiful Ocean County, N.J., Jackson is located within a short drive from the Jersey Shore and about an hour's drive to New York City or Philadelphia. The township was incorporated in 1844. Visit Jackson Township's website at www.jacksontwpnj.net for more information.
View original content:
SOURCE Jackson Township, NJ
|
https://www.kxii.com/prnewswire/2022/06/14/jackson-township-enters-into-settlement-agreement-with-us-department-justice/
| 2022-06-15T00:57:36 |
CLEVELAND, June 24, 2022 /PRNewswire/ -- Yogurt consumption, and demand for related packaging, has been steadily on the wane since the Greek yogurt trend peaked around 2015. Then the pandemic happened.
As consumers ate more meals at home, they also purchased more yogurt, including trying new brands and formats. Interest in yogurt as both a healthy snack and a better-for-you dessert rose, driving numerous introductions of innovative yogurt styles and flavor profiles, many premium items.
This had a significant impact on the $566 million market for yogurt packaging in the US, according to the Freedonia Group.
In a newly published analysis, the market research firm finds that the increase in yogurt consumption during the pandemic promoted demand for yogurt packaging such as single-serve cups, pouches, and bottles, and particularly larger bulk-volume tubs and pouches. Additionally, increased demand for sustainable packaging – which often costs more – promoted value gains. However, market maturity in the key spoonable segment continued to weigh down growth.
As in the larger food industry, improving packaging sustainability is an important goal of yogurt brands and their packaging suppliers, with reducing the use of virgin plastics and improving recyclability representing key targets of these efforts. For example:
- A growing number of yogurt producers are looking for ways to increase their use of paper, which is recycled at higher rates than plastic and has a sustainable, high-value image. Notably, in August 2021, Chobani launched a paper cup for its oat milk-based yogurt product line.
- Suppliers of plastic packaging are looking for ways to increase recycling rates and the use of recycled plastic content, but also to benefit from the appeal of paper with the use of higher-end wrap labels.
Additional strategies suppliers are pursuing to make yogurt packaging more sustainable include:
- innovations that make plastic easier to recycle (e.g., monolayer pouches)
- development of compostable and/or degradable alternative packaging materials
- source reduction efforts like replacing rigid lids with plastic or foil lidding
Yogurt Packaging, now available from the Freedonia Group, provides historical data (2010, 2015, and 2020) and forecasts for 2025 for yogurt packaging demand by value in current dollars (including inflation) by application, product, and material.
- spoonable yogurt
- squeezable yogurt
- drinkable yogurt
- cups
- tubs
- bottles and jars
- pouches (e.g., pillow, stand-up, and side seal) and bags
- boxes and folding cartons
- other yogurt packaging (e.g., lidding, sleeves)
- plastic (including bioplastics)
- other materials (e.g., paper and paperboard, glass, foil)
About the Freedonia Group - The Freedonia Group, a division of MarketResearch.com, is the premier international industrial research company, providing our clients with product analyses, market forecasts, industry trends, and market share information. From one-person consulting firms to global conglomerates, our analysts provide companies with unbiased, reliable industry market research and analysis to help them make important business decisions. With over 100 studies published annually, we support over 90% of the industrial Fortune 500 companies. Find off-the-shelf studies at https://www.freedoniagroup.com/ or contact us for custom research: +1 440.842.2400.
Press Contact:
Corinne Gangloff
+1 440.842.2400
[email protected]
View original content to download multimedia:
SOURCE The Freedonia Group
|
https://www.mysuncoast.com/prnewswire/2022/06/24/pandemic-gave-yogurt-consumption-needed-boost/
| 2022-06-24T14:54:18 |
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Ofer Yardeni, Chairman and CEO of Stonehenge NYC, announced today that the company has closed on the purchase of 780 Greenwich Street, New York, New York. The six-story, 70,000 sq. ft. building, which contains 88 residential units, commands a full 148 sq. ft. blockfront in Manhattan's West Village. The property was built in 1950.
780 Greenwich is situated on Greenwich Street between Bank and Bethune Streets in the heart of the West Village, one of the city's most desirable neighborhoods. This pet-friendly, doorman building is close to many of the city's most vibrant restaurants, shops, and nightlife offerings and is only steps away from the Meatpacking District, the Highline, as well as the Hudson River Esplanade. 780 Greenwich will join 26 other buildings in the Stonehenge NYC portfolio. The property offers duplex units, a rarity in the West Village.
"We are excited to expand Stonehenge's presence in the West Village. 780 Greenwich Street represents a true trophy asset as it is one of the few rental buildings in the Village with more than 75 large apartments. I am pleased to say that with this off-market acquisition, Stonehenge NYC now manages two of these rare assets, the other being 10 Downing Street, located just blocks away. We look forward to providing a first-class experience to the residents of 780 Greenwich," said Mr. Yardeni.
This off-market deal was sourced by Stonehenge NYC which also led the underwriting and due diligence. The company will manage the property, as it does its entire portfolio. Stonehenge NYC plans to upgrade the building's apartments and amenities to the high standard found throughout its portfolio. The company plans to utilize its best-in-class property management team, technology platform, and lifestyle offerings to enhance the resident experience. Tenants will be able sign leases online, utilize a user-friendly tenant app on their smartphones, and join the Stonehenge community of over 5,000 New Yorkers.
Stonehenge NYC, founded by Ofer Yardeni, is a vertically integrated, private real estate company with expertise in investment management, property management, development, design, construction, leasing and financing. Stonehenge NYC's core growth strategy is focused on New York City real estate opportunities. The company currently owns and manages 27 residential apartment buildings with more than 3,300 rental apartment units and 150,000 square feet of retail and professional space. www.stonehengenyc.com
View original content to download multimedia:
SOURCE Stonehenge NYC
|
https://www.wibw.com/prnewswire/2022/08/25/stonehenge-nyc-buys-luxury-west-village-building-780-greenwich-street/
| 2022-08-25T19:23:58 |
23 of the world’s best sandwiches
By Terry Ward, CNN
Is there a food more humble yet universally adored than the sandwich?
And while one person’s go-to hamburger snack might be another’s katsu sando or chivito, there’s hardly a country on the planet that doesn’t turn to some type of bread with something stuffed inside it to cure a craving.
Traveling the world’s sandwiches is, in a way, like traveling the world.
To help narrow your choices for the sandwich to plan your next trip around, here are 23 of the world’s best sandwiches:
Pambazo, Mexico
Tortillas might first come to mind when it comes to Mexico. But one of the country’s most famous antojitos (street snacks or appetizers) is the pambazo, a favorite street food sandwich from Veracruz and Puebla said to have been inspired by the shape of a Mexican volcano.
It’s a seriously filling thing featuring bread tinted red thanks to a soak in slightly spicy guajillo sauce. Open up wide for the potatoes and Mexican chorizo inside, topped with lettuce, cheese and cream.
Tramezzino, Italy
While originally from Turin, Venice has taken this popular lunchtime bar snack to the next level — properly stuffing English tea style-triangles of white bread with fillings that include everything from olives and tuna, soft boiled eggs and vegetables to piles of crispy prosciutto with truffle.
Bars all over Venice pull out platters of tramezzini at lunchtime. If you’re doing things right, you’re enjoying them canal-side with a glass of local wine.
Shawarma, Middle East
Shawarma’s name comes from the Arabic word for “turning” — a reference to how this favorite Middle Eastern sandwich’s meaty filling cooks on a vertical spit. In adaptations that spread to the Mediterranean and Europe, shawarma has been reinterpreted as gyro in Greece or doner kebab in Germany, via Turkey.
While there are many variations of this popular street food, its base is grilled spiced meat (usually chicken, lamb or beef) shaved from the rotisserie and tucked into a light sleeve of pita bread, topped with things such as tomatoes, onions and parsley and perhaps tahini sauce and hot sauce, too.
Bánh mì, Vietnam
A culinary remnant of French colonialism, the baguette sandwich was reinterpreted to their own taste by the Vietnamese. Bánh mì are now sold from food carts on nearly every street corner in Ho Chi Minh City and across Vietnam and are widely loved well beyond the country’s borders.
The classic version is pork-based, starring chả lụa (Vietnamese-style pork roll), shredded pickled carrots, pickled daikon, cilantro leaves, mayonnaise and other ingredients. You can find variations with tofu and thinly sliced lemongrass chicken, too. The taste is crunchy, fresh, savory and utterly delicious.
Muffaletta, New Orleans, United States
Italian immigrants who settled into New Orleans’ Lower French Quarter in the late 19th and early 20th century are to thank for inventing this quintessential New Orleans sandwich made from round, sesame-covered loaves of Sicilian bread that can easily outsize your head.
Inside the muffaletta, layers of chopped olives, Genoa salami, ham and various cheeses (often with Swiss and provolone) mingle to mouthwatering effect.
Chivito, Uruguay
While this Uruguayan sandwich’s name translates to “little goat,” that ruminant’s meat is decidedly absent from this decadent assemblage of thinly sliced steak (called churrasco), ham, bacon, lettuce, mayonnaise and melted mozzarella.
Piled high into a roll that’s similar to a hamburger bun or ciabatta, the chivito is customarily topped off with a fried egg — just to make sure you don’t leave hungry.
Pan bagnat, France
If you like a good salade Niçoise, chances are you’ll be a fan of the pan bagnat — a sandwich that similarly hails from Nice in the South of France and is made using crusty pain de campagne, a boulangerie favorite.
Sliced in half (but not completely through), the bread hinges open to reveal layers of raw vegetables, anchovies, olives, sliced hard boiled eggs, chunks of tuna and liberally applied olive oil, salt and pepper. Bon appétit, indeed.
Smørrebrød, Denmark
Beloved all over Scandinavia but particularly iconic for being one of Denmark’s national dishes, this open-faced sandwich translates to “buttered bread”– but smørrebrød is so much more.
With rye bread as the typical base, toppings include scores (perhaps hundreds) of combinations that range from curried or pickled herring and tiny pink shrimp to sliced boiled eggs and rare roast beef atop a layer of butter. In true Scandi style, smørrebrød goes big on aesthetics, too — the sandwiches are as pretty to look at as they are delicious to eat.
Spatlo, South Africa
Particularly linked to the Gauteng province and Johannesburg, South Africa’s spatlo sandwich (often called kota, loosely translated as quarter) is made from a quarter loaf of bread that’s been hollowed out and stacked to the max with meat and much more.
Inside, find seasoned fries, cheese, bacon, polony (bologna), Russian-style sausage and perhaps a heaping of spicy atchar sauce (made from green mangoes) and a fried egg.
Montreal smoked meat sandwich, Canada
Carnivores say oui to this seriously stacked sandwich from Quebec made with smoked beef brisket layered between slices of light rye bread and drizzled with tangy yellow mustard.
The best briskets used in a true Montreal smoked meat sandwich are said to soak for up to two weeks in brine and savory aromatics such as coriander, peppercorn and garlic before being smoked and hand-sliced to go down in eternal sandwich glory.
Po’boy, New Orleans, United States
A classic belly buster that traces its roots to New Orleans, the po’boy (aka poor boy) is rumored to have been invented to feed the city’s streetcar drivers during a 1929 strike.
The history remains fuzzy, but the taste of this sandwich certainly is not.
Folks who sink their teeth into this mayonnaise-laden French bread stuffed with fried oysters (or perhaps fried shrimp or roast beef) and piled with lettuce, tomato and pickles is in for one beautifully delicious mess.
Fricassé, Tunisia
With a comforting deep fried yeast bun for an exterior and a savory mashup of tuna, potatoes and boiled egg inside, this North African sandwich delivers a filling feed in a deceptively small package.
Tunisia’s favorite picnic and street food sandwich, the fricassé, often gets livened up with additions such as sliced black olives, preserved lemon and harissa — the ubiquitous spicy condiment in this part of the world made from dried red chili peppers, garlic and a spice mix that usually includes caraway, cumin and coriander seed.
Cuban sandwich, Cuba/United States
Originally a luxury item in Cuba, according to Andy Huse, the author of a forthcoming book on the Cuban sandwich, this Florida favorite is cause for constant debate in Miami and Tampa, where purists spar over its fundamental ingredients as well as its origin.
Whether you take yours with salami (à la Tampa) or not (à la Miami), this sandwich layered with boiled ham, roasted pork, pickles, mustard, Swiss cheese and butter and pressed between pieces of fluffy Cuban bread is a simple, hearty and most often affordable feed.
Cucumber sandwich, United Kingdom
On the dainty side of the sandwich spectrum, cucumber sandwiches are a traditional English afternoon tea staple, often spotted on the same tiered platters with scones and mini-pastries.
Extra soft white bread with the crusts removed gets layered with razor-thin English cucumbers (peeled, please, then lightly salted and drained), butter, a light dusting of fine pepper and perhaps a spray of fresh herbs such as dill. Cut the sandwich into neat triangles and pair with a pot of tea.
Chip butty, United Kingdom
The opposite of elegant, the chip butty means business — after all, this is a sandwich sheathed in buttered white bread and stuffed with fries (aka chips in its native Britain) that seem to carve out their own space in all that soft goodness.
Said to trace its roots all the way back to the 1860s and a seaside fish and chips shop in Lancashire, England, the chip butty can be doused with optional condiments ranging from ketchup and malt vinegar to mayonnaise.
Katsu sando, Japan
A deep-fried pork cutlet — pounded and breaded with panko and tucked into a fluffy Japanese white milk bread called shokupan — is the base for this cult-favorite, convenience store snack from Japan.
Considered yōshoku cuisine (Western-influenced), katsu sando is usually garnished with ribbons of cabbage and comes in chicken and egg salad (tamago) versions, too.
Reuben, United States
Ask people from Nebraska, and they’ll say the Reuben was invented there by a local grocer looking to feed a band of hungry poker players. In New York, the story goes that the sloppily sinful sandwich on rye bread was named for the founder of New York’s Reuben Restaurant.
What’s not disputable is the goodness crammed inside a Reuben — sliced corned beef, sauerkraut, Swiss cheese and Russian or Thousand Island-style dressing. You’ll need napkins. Lots.
Croque monsieur/madame, France
An archetypal sandwich from France that originated as “un snack” in French cafes, this crunchy (croquant) marvel comes in female and male incarnations (madame et monsieur).
For the croque monsieur, slices of white bread topped with grated cheese and stuffed with thinly sliced ham and emmental or gruyere inside are dipped into egg batter and fried. For the croque madame, the egg component is served fried atop the sandwich instead.
Philly cheesesteak, Philadelphia, United States
Mouthwateringly simple, the City of Brotherly Love’s most beloved sandwich is a delectable hot mess layered with ribeye steak sliced thin, oozing sheets of provolone and sauteed peppers and onions to your liking.
Purists insist the Philly cheesesteak is enveloped inside a hoagie bun. But if you’re whipping one up at home, any thick white bread is sure to be satisfying.
Broodje haring, Netherlands
Like a taste of the salty North Sea distilled into sandwich form, this classic Dutch sandwich is for serious seafood fans only.
Served cold, broodje haring features crunchy baguette-style bread filled with thin slices of chilled herring that’s been cured in salt and piled with diced onions. Depending on where you are in the Netherlands, it might have sliced gherkins, too. Look for it anywhere there’s a market at the stalls called vishandels.
Falafel pita, Middle East
You won’t miss meat in this vegetarian staple of Middle Eastern cuisine. The falafel pita is exactly what its name suggests. Crunchy fried balls of falafel — made from soaked, ground-up chickpeas mixed with herbs — are pushed into a warm and fluffy pita pocket and brightened up with lettuce, tomatoes, tangy tahini sauce and other additions that might include chili sauce and hummus.
You’ll find people lining up for this sandwich on the streets of Beirut, Amman and many other places across the Middle East and beyond.
Choripán, Argentina
Sausages splashed with mustard and chimichurri sauce are the savory makings of this classic Argentinean mouthful whose name is a mash-up of chorizo (sausage) and pan (bread).
Choripán’s origins are thought to trace back to the country’s cowboys called gauchos, known for their grilled meat asados. But today, the casual and filling sandwich is found beyond Buenos Aires and the Andes at food carts, futbol games and restaurants across South America. It’s best enjoyed hot off the grill.
Lobster roll, New England, United States
New Englanders hold their humble lobster roll dear — a summertime coastal treat piled with big chunks of steamed lobster meat that’s usually mixed with lemon juice, mayonnaise and herbs and tucked into a roll resembling a hot dog bun.
You can find them at seafood restaurants across the United States. But a classic lobster shack on the stretch of coastline from Maine to Connecticut will make for a scenic backdrop that’s hard to beat.
The-CNN-Wire
™ & © 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.
|
https://localnews8.com/entertainment/cnn-style/2022/05/11/23-of-the-worlds-best-sandwiches/
| 2022-05-11T15:29:29 |
NEW YORK, July 27, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Unity Software, Inc. (U), relating to its proposed merger with ironSource Ltd. Under the terms of the agreement, Unity shareholders are expected to own approximately 73.5% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/unity-software-inc. It is free and there is no cost or obligation to you.
About Monteverde & Associates PC
We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.
If you own common stock in U and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2022 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:
SOURCE Monteverde & Associates PC
|
https://www.wibw.com/prnewswire/2022/07/27/shareholder-alert-mampa-class-action-firm-announces-investigation-unity-software-inc-u/
| 2022-07-27T23:12:19 |
Infor Provides Simple Migration to Newest Iteration of Infor Public Sector Applications
NEW YORK, Aug. 18, 2022 /PRNewswire/ -- Infor, the industry cloud company, announced today the successful upgrade of Infor Public Sector (IPS) asset and work management software at The City of Calgary, based in Alberta, Canada, has successfully upgraded to the latest iteration. This upgrade will allow The City of Calgary, Mobility business unit, to capitalize on newer functionalities, including mobile applications, GIS data integration, overhauled user interface and enhanced performance. The upgrade was implemented by Infor's Consulting Services (ICS) and will assist The City of Calgary to mitigate risk on its critical assets, leading to improved outcomes for the citizens of Calgary.
"Infor has continued to work as a partner with The City of Calgary for many years, and we've been looking forward to update our software for asset and work management to take advantage of new modern features that will enable more autonomy over our assets," said Miles Dyck, Service Design Manager. "We trust that these applications will continue to help us further streamline processes and improve operations, management, maintenance and customer service."
Working alongside Infor ICS, which provides organizations with a clear, simple path for upgrading or migrating an existing Infor solution, The City of Calgary gained a completely new version of their Infor solutions - which provides the public sector-specific functionality needed to ensure efficient business operations. With this software, The City of Calgary can potentially make faster, better-informed decisions related to asset tracking and valuation, work management, preventive maintenance scheduling, work order management, and advanced asset analysis.
"Infor has a deep understanding of the very specific needs of our public sector clients, and our applications are exactly what they're looking for to excel," said Matt Breslin, executive vice president and general manager, Infor. "Knowing the vast range of challenges our clients face, including intense cost pressures and constantly shifting regulations, we've designed a simple and efficient solution with a proven track record of success. It's exciting to consider the lasting impact our solutions can have for our public sector clients far into the future."
Infor Public Sector is an industry-specific software platform that encompasses a comprehensive suite of solutions unique to federal, state and local government organizations. For more information please visit https://www.infor.com/industries/state-local-government.
About Infor
Infor is a global leader in business cloud software specialized by industry. We develop complete solutions for our focus industries. Infor's mission-critical enterprise applications and services are designed to deliver sustainable operational advantages with security and faster time to value. Over 60,000 organizations in more than 175 countries rely on Infor's 17,000 employees to help achieve their business goals. As a Koch company, our financial strength, ownership structure, and long-term view empower us to foster enduring, mutually beneficial relationships with our customers. Visit www.infor.com
For more information:
Christina Ledger
Infor
[email protected]
(312) 662-2135
Copyright ©2022 Infor. All rights reserved. The word and design marks set forth herein are trademarks and/or registered trademarks of Infor and/or related affiliates and subsidiaries. All other trademarks listed herein are the property of their respective owners. www.infor.com
This announcement reflects the direction Infor may take with regard to the specific product(s) described herein, all of which is subject to change by Infor in its sole discretion, with or without notice to you. This announcement is not a commitment to you in any way and you should not rely on this document or any of its content in making any decision. Infor is not committing to develop or deliver any specified enhancement, upgrade, product or functionality, even if such is described in this announcement and even if such description is accompanied by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "predict," "should," "will," and/or similar expressions. Many factors can affect Infor's product development plans and the nature, content and timing of future product releases, all of which remain in the sole discretion of Infor. This announcement, in whole or in part, may not be incorporated into any contractual agreement with Infor or its subsidiaries or affiliates. Infor expressly disclaims any liability with respect to this announcement.
View original content to download multimedia:
SOURCE Infor
|
https://www.wibw.com/prnewswire/2022/08/18/city-calgary-simplifies-asset-management-with-infor/
| 2022-08-18T14:05:45 |
WHO convenes experts to decide if monkeypox is an emergency
GENEVA (AP) — The World Health Organization will convene an emergency committee of experts to determine if the expanding monkeypox outbreak that has mysteriously spread outside Africa should be considered a global health emergency.
WHO Director-General Tedros Adhanom Ghebreyesus said Tuesday he decided to convene the emergency committee on June 23 because the virus has shown “unusual” recent behavior by spreading in countries well beyond parts of Africa, where it is endemic.
“We believe that it needs also some coordinated response because of the geographic spread,” he told reporters.
Declaring monkeypox to be an international health emergency would give it the same designation as the COVID-19 pandemic and mean that WHO considers the normally rare disease a continuing threat to countries globally.
The U.K. said Monday it had 470 cases of monkeypox across the country, with the vast majority in gay or bisexual men. British scientists said last week they could not tell if the spread of the disease in the U.K. had peaked.
The meeting of outside experts could also help improve understanding and knowledge about the virus, Tedros said, as WHO released new guidelines about vaccinating against monkeypox.
The U.N. health agency does not recommend mass vaccination, but advises the “judicious” use of vaccines. It said controlling the disease relies primarily on measures like surveillance, tracking cases and isolating patients.
Last month, a leading adviser to the World Health Organization said the outbreak in Europe and beyond was likely spread by sex at two recent raves in Spain and Belgium.
Scientists warn that anyone, regardless of sexual orientation, is susceptible to catching monkeypox if they are in close, physical contact with an infected person or their clothing or bed sheets.
WHO has been working with partner countries to create a mechanism by which some vaccines for smallpox – a related disease – might be made available to countries that are affected, as research continues into their effectiveness against the new outbreak.
Tedros said more than 1,600 cases and nearly 1,500 suspected cases have been reported this year in 39 countries, including seven where monkeypox has been reported for years. A total of 72 deaths have been reported but none in the newly affected countries, which include Britain, Canada, Italy, Poland, Spain and the United States.
The ongoing outbreak of monkeypox in Europe and elsewhere marks the first time the disease has been known to spread among people who have no travel links to Africa.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wibw.com/2022/06/14/who-convenes-experts-decide-if-monkeypox-is-an-emergency/
| 2022-06-14T16:17:12 |
Experience the difference. The one and only professional business book for entrepreneurs, college students, startups, and business owners worldwide
WOODBRIDGE, Va., May 25, 2022 /PRNewswire/ -- Mayfair Delivery Corporation announces today a new book from Founder, CEO, Author Prince Nana
https://store.bookbaby.com/bookshop/book/index.aspx?bookURL=HOW-TO-START-and-OPERATE-A-SUCCESSFUL-BUSINESS&b=p_fr-ho-wh titled, "How To Start & Operate A Successful Business: The Trusted Professional Step-By-Step Guide." Published by BookBaby, the new book offers exceptional steps for entrepreneurial and startup success into business ownership, with professional insights on business development and generational wealth building strategies. , "How To Start & Operate A Successful Business" is now available in e-book and paperback on online bookstores worldwide.
With 20 years of Corporate Executive Leadership roles, Prince has written this booked sponsored by Mayfair Delivery Corporation to share his practical insights and professional wisdom on "HOW TO START & OPERATE A SUCESSFUL BUSINESS" from anywhere in the world. With the understanding that startups and the entrepreneurship journey require secrets and formulas for success, Prince keys in on the factors that marketing and advertising are the bottom-line foundations for branding success and development, and selling and buying are the two key daily transactions that allows businesses and companies to grow in the global economy.
"HOW TO START & OPERATE A SUCESSFUL BUSINESS" will provide you with the step-by-step knowledge and resourceful information to be adequately equipped to start, build, and operate your own business in any industry and market worldwide. "HOW TO START & OPERATE A SUCESSFUL BUSINESS" is designed to educate, inform, and offer you the keys to open the doors to your own success and future. The book will put you in the driver's seat and guide you through the steps of developing a startup company or advancing your current business and going to the next level.
What You Get In The Book:
*Global & Corporate Executive Assets Management
*Business Formation
*Financial Institution Establishment
*Global Industry & Market
*Logos, Trademarks, Patents, Copyright
*Networking & Social Media
*Branding & Advertising
*IRS Tax Forms & Proper Usage
*Accounting & Bookkeeping
*Stocks & Investments
*Loans & Funding
*Life Insurance & Generational Wealth Building
Contact:
Mayfair Yates | Mayfair Delivery Corporation
[email protected]
View original content to download multimedia:
SOURCE Mayfair Delivery Corporation
|
https://www.wibw.com/prnewswire/2022/05/25/mayfair-delivery-corporation-announces-latest-book-prince-nana-how-start-amp-operate-successful-business-trusted-professional-step-by-step-guide/
| 2022-05-25T21:10:53 |
BEIJING, May 16, 2022 /PRNewswire/ -- AGM Group Holdings Inc. ("AGMH" or the "Company") (NASDAQ: AGMH), an integrated technology company focusing on providing fintech software services and producing high-performance hardware and computing equipment, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2022. The annual report can be accessed on the Company's website at https://www.agmprime.com/annual-results/ and on the SEC's website at https://www.sec.gov/.
The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company's Investor Relations Department at [email protected].
About AGM Group Holdings Inc.
Incorporated in April 2015 and headquartered in Beijing, China, AGM Group Holdings Inc. (NASDAQ: AGMH) is an integrated technology company focusing on providing fintech software services and producing high-performance hardware and computing equipment. AGMH's mission is to become one of the key participants and contributors in the global fintech and blockchain ecosystem. For more information, please visit www.agmprime.com.
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties, Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.
For more information, please contact:
In China:
At the Company:
Email: [email protected]
Email: [email protected]
The Blueshirt Group
Ms. Feifei Shen
Phone: +86 13466566136
Email: [email protected]
In the United States:
The Blueshirt Group
Ms. Julia Qian
Phone: +1 973-619-3227
Email: [email protected]
View original content:
SOURCE AGM Group Holdings Inc.
|
https://www.kxii.com/prnewswire/2022/05/16/agm-group-files-annual-report-form-20-f-fiscal-year-2021/
| 2022-05-16T23:20:54 |
$111 Million Equity Investment Round to Support Continued Development and Deployment of ApiJect's Proprietary High-Volume Manufacturing Platform for Single-Dose Prefilled Injection Devices.
STAMFORD, Conn., May 18, 2022 /PRNewswire/ -- ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced today that it had completed a $111 million private round of investment.
This investment round values ApiJect at approximately $300 million.
The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest in addition to equity. Jefferies and ApiJect's other lenders also converted all of their debt into ApiJect equity, such that following this transaction, ApiJect has no debt on its balance sheet.
The funds will be used for continued development of ApiJect's proprietary Blow-Fill-Seal (BFS) plastic prefilled injection system, to deploy its equipment and proprietary technologies to licensees, and for general working capital purposes. Royalty Pharma and Jefferies are represented on ApiJect's Board of Directors, along with ApiJect co-founders Jay Walker and Marc Koska, and Hanjin In, the CEO of Tae-Chang Industrial Co., Ltd., ApiJect's South Korean cannula supplier.
ApiJect is developing an innovative portfolio of drug delivery devices using high-speed BFS manufacturing, which is recognized by the FDA as an advanced aseptic process that forms, fills and seals a single unit dose in a continuous, automated manufacturing step. BFS technology greatly reduces the risk of contamination and error during one of the most critical steps of drug production. BFS is cost-efficient for short and long runs, and highly suitable to scale quickly in order to meet unexpected spikes in demand such as for a rapid response to population-scale health emergencies. Advancements developed by ApiJect for temperature management now enable BFS manufacturing of a vast array of sterile injectable drugs, including ultra-cold mRNA vaccines.
ApiJect Chief Executive Officer Jay Walker commented: "This is an important day for injection device innovation, and, with that, the future health of billions of people throughout the world. The investment provided by Royalty Pharma and Jefferies supports further development of an injection technology that can scale rapidly and efficiently to meet global demand for injectable medicines."
Mr. Walker further said: "We welcome Royalty Pharma's commitment to the ApiJect mission. Royalty Pharma has a proven track record in selecting successful partners and in assisting in advancing its partners' goals. We could not ask for a better strategic partner from within the pharma industry. In Jefferies, we have a partner that has been with us from virtually the beginning of ApiJect."
"We are delighted to form this win-win partnership with ApiJect," said Pablo Legorreta, Royalty Pharma's Founder and Chief Executive Officer. "The global pandemic highlighted the clear unmet need for a new kind of prefilled syringe that can be rapidly produced to respond to public health threats, and at massive scale that would be capable of delivering hundreds of millions, potentially billions, of doses to people in the U.S. as well as globally. ApiJect is developing a truly innovative technology, that could transform the manufacturing and delivery of life-saving injectable drugs in a way that would also make these medicines safer and more readily accessible for patients around the world."
"We are proud of our association with ApiJect and believe strongly that their solutions will be a positive gamechanger in many of the most critical aspects of improving health globally," said Rich Handler, CEO of Jefferies.
The first potential device made on the ApiJect Platform is the Prefilled ApiJect Injector, a single-dose prefilled injector designed to efficiently deliver a 0.5mL dose into a patient with a simple squeeze of the BFS container by the healthcare professional. This new type of prefilled injector will be ApiJect's first product submitted for regulatory review and approval. The Prefilled ApiJect Injector and its manufacturing process include:
- An aseptically filled single-dose container, designed to enable efficient and intuitive injection administration.
- A pen-needle-style hub (including a patented connector for BFS container interface and Needle Hub mounting) that turns the BFS container into an injection device.
- Innovations in temperature management to expand the range of medicines and vaccines suitable for BFS packaging.
ApiJect recently launched its Technology Development Center in the greater Orlando area to bring to the U.S. critical capabilities for device design and engineering, and BFS mold development, as well as for small-scale manufacturing of single-dose, prefilled injectors and other injectable devices. Its purpose is to dramatically reduce the time and processes necessary for product development. ApiJect's Technology Development Center supports the company's existing fill-finish lines at its manufacturing partner site in South Carolina, which currently has the capacity to produce up to 540 million single-dose prefilled injectors annually.
About ApiJect Systems
ApiJect Systems, Corp., is a public-benefit medical technology company working to use our platform to bring more prefilled, single-dose injections to patients everywhere. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own Blow-Fill-Seal packaging lines with ApiJect-licensed technology, or at one of ApiJect's world-class manufacturing partners.
View original content to download multimedia:
SOURCE ApiJect Systems Corp.
|
https://www.mysuncoast.com/prnewswire/2022/05/18/apiject-announces-investment-by-royalty-pharma-jefferies/
| 2022-05-18T19:34:00 |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 353